var title_f43_16_44288="CMV focal cytopathic changes";
var content_f43_16_44288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CMV focal cytopathic changes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cell culture monolayer of human foreskin fibroblast cells, showing typical focal cytopathic effect of CMV.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44288=[""].join("\n");
var outline_f43_16_44288=null;
var title_f43_16_44289="Corneal ulcers fluorescein";
var content_f43_16_44289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corneal infiltrates or ulcers with fluorescein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two small corneal areas of fluorescein staining (indicated by the arrows) that are either infiltrates or ulcers are shown with ultraviolet illumination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lawrence B Stack, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44289=[""].join("\n");
var outline_f43_16_44289=null;
var title_f43_16_44290="Inflamed pterygium extending toward visual axis";
var content_f43_16_44290=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Inflamed pterygium extending toward visual axis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Christopher J. Rapuano, MD. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44290=[""].join("\n");
var outline_f43_16_44290=null;
var title_f43_16_44291="Leiomyosarcoma gastric UGI";
var content_f43_16_44291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leiomyosarcoma of the stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 218px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast upper gastrointestinal study demonstrates a large irregular polypoid mass arising from the greater curvature of the stomach. Irregular masses arising from this site are typically malignant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44291=[""].join("\n");
var outline_f43_16_44291=null;
var title_f43_16_44292="Guaifenesin, dextromethorphan, and phenylephrine: Drug information";
var content_f43_16_44292=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Guaifenesin, dextromethorphan, and phenylephrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/44/7877?source=see_link\">",
"    see \"Guaifenesin, dextromethorphan, and phenylephrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1698817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maxiphen DM [DSC];",
"     </li>",
"     <li>",
"      Maxiphen DMX;",
"     </li>",
"     <li>",
"      Mucinex&reg; Children&rsquo;s Multi-Symptom Cold [OTC];",
"     </li>",
"     <li>",
"      Robafen CF Cough &amp; Cold [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Children's Cough &amp; Cold CF [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Maximum Strength Multi-Symptom Cold [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Multi-Symptom Cold [OTC];",
"     </li>",
"     <li>",
"      SINUtuss&reg; DM [DSC];",
"     </li>",
"     <li>",
"      Tusso&trade;-DMR [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F1699136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Decongestant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F1699161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also refer to specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Relief of nasal/sinus congestion and cough:",
"     </b>",
"     Tablet: Oral (Maxiphen DM): One tablet every 4-6 hours, not to exceed 4 tablets/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F1699160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also refer to specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Relief of nasal/sinus congestion and cough:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablet: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 6-11 years (Maxiphen DM): One-half tablet every 4-6 hours, not to exceed 2 tablets/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Liquid (OTC labeling): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 4-5 years (Children&rsquo;s Robitussin &reg; Cough and Cold CF, Children&rsquo;s Mucinex&reg; Multi-Symptom Cold): Oral: 5 mL every 4 hours, not to exceed 30 mL/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 6-11 years (Children&rsquo;s Robitussin &reg;Cough and Cold CF, Children&rsquo;s Mucinex&reg; Multi-Symptom Cold): Oral: 10 mL every 4 hours, not to exceed 60 mL/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F1699162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1699168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maxiphen DMX: Guaifenesin 200 mg, dextromethorphan hydrobromide 20 mg, and phenylephrine hydrochloride 10 mg per 5 mL (473 mL) [sugar free; contains ethanol 0.1%, propylene glycol; orange cream flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mucinex&reg; Children&rsquo;s Multi-Symptom Cold: Guaifenesin 100 mg, dextromethorphan hydrobromide 5 mg, and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL) [ethanol free; contains propylene glycol and sodium 3 mg/5 mL; very berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Robitussin&reg; Children's Cough &amp; Cold CF: Guaifenesin 50 mg, dextromethorphan hydrobromide 5 mg, and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL) [ethanol free; contains propylene glycol, sodium 3 mg/5 mL, and sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Robitussin&reg; Peak Cold Maximum Strength Multi-Symptom Cold: Guaifenesin 200 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 5 mL (118 mL, 237 mL) [contains menthol, propylene glycol, sodium 3 mg/5 mL, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Robitussin&reg; Peak Cold Multi-Symptom Cold: Guaifenesin 100 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 5 mL (118 mL, 237 mL) [contains menthol, propylene glycol, sodium 3 mg/5 mL, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Robafen CF Cough &amp; Cold: Guaifenesin 100 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 5 mL (120 mL, 240 mL,) [ethanol free; contains propylene glycol and sodium benzoate; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral [scored]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maxiphen DM: Guaifenesin 400 mg, dextromethorphan hydrobromide 20 mg, and phenylephrine hydrochloride 10 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F1698818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1699137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of dry nonproductive coughs and upper respiratory symptoms associated with hay fever, colds, or the flu",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4473167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions which follow have been reported with the combination product; see individual drug monographs for additional adverse reactions that may be expected from each agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Cardiovascular collapse, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Anxiety, CNS depression, convulsions, dizziness, drowsiness, excitability increased, fear, hallucinations, headache, insomnia, irritability increased, lightheadedness, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Respiratory difficulties",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1699142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to guaifenesin, dextromethorphan, phenylephrine, sympathetic amines, or any component of the formulation; severe hypertension; coronary disease; prostatic hypertrophy; breast-feeding; use with or within 14 days of  MAO inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1699143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated, sedated and/or patients confined to the supine position.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in atopic children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: Appropriate use: Underlying cause of cough should be determined prior to prescribing.  Re-evaluate if cough persists &gt;7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self medication (OTC), notify healthcare provider if symptoms do not improve within 7 days, or are accompanied by fever, rash, or persistent headache.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F1699150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1699149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1699139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F1699141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Giltuss TR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-14-288 mg (100): $93.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Exactuss Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-28-388 mg/5 mL (473 mL): $7.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (G-Tusicof Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-20-400 mg/5 mL (474 mL): $30.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Giltuss Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-28-388 mg/5 mL (237 mL): $26.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Giltuss Pediatric Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-7.5-88 mg/mL (60 mL): $22.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Mucinex Child Cold Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-5-100 mg/5 mL (118 mL): $7.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Mucinex Fast-Max Congest Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-20-400 mg/20 mL (180 mL): $10.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Nortuss-DE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-5-50 mg/mL (30 mL): $10.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Child Cough/Cold CF Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-5-50 mg/5 mL (118 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Cough/Cold CF Max Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-10-200 mg/5 mL (118 mL): $5.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Cough/Cold CF Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-10-100 mg/5 mL (237 mL): $7.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Multi-Symptom Max Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-10-200 mg/5 mL (118 mL): $5.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Peak Cold Multi-Sym Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-10-100 mg/5 mL (118 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin To Go Cough/Cold CF Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-10-100 mg/5 mL (10 mL): $0.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tusicof Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-20-400 mg/5 mL (120 mL): $13.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tussafed EX Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-30-200 mg/5 mL (118 mL): $8.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tussi-Pres Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-10-200 mg/5 mL (10 mL): $1.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Wal-Tussin CF Max Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-10-200 mg/5 mL (237 mL): $8.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Broncotron-D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-40-400 mg/10 mL (118.3 mL): $14.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Giltuss TR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-30-600 mg (100): $90.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Giltuss TR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-28-388 mg (100): $110.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tusicof Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-20-400 mg (60): $27.00",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1699155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1699157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8807 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44292=[""].join("\n");
var outline_f43_16_44292=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698817\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699136\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699161\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699160\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699162\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699168\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698818\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699137\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4473167\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699142\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699143\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699150\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699149\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699139\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699141\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322881\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699155\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1699157\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8807\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8807|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/44/7877?source=related_link\">",
"      Guaifenesin, dextromethorphan, and phenylephrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_16_44293="Diabetic papillopathy";
var content_f43_16_44293=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diabetic papillopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/16/44293/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44293/contributors\">",
"     Madhura Tamhankar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44293/contributors\">",
"     Nicholas J Volpe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/16/44293/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44293/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/16/44293/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44293/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/16/44293/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic papillopathy (DP) is a term that is used to characterize a finding of unilateral or bilateral optic disc edema with variable visual loss in a patient with diabetes. Specific criteria for the diagnosis of diabetic papillopathy and a clear differentiation of this entity from nonarteritic anterior ischemic optic neuropathy (NAION) have not been established. While diabetic papillopathy has a generally favorable prognosis and does not usually require treatment, it must be distinguished from more malignant processes such as papilledema secondary to increased intracranial pressure.",
"   </p>",
"   <p>",
"    This topic discusses diabetic papillopathy. NAION and other conditions causing optic disc swelling are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20442?source=see_link\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27558?source=see_link\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9929?source=see_link\">",
"     \"Nonarteritic ischemic optic neuropathy: Prognosis and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30552?source=see_link\">",
"     \"Overview and differential diagnosis of papilledema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer than 125 cases of diabetic papillopathy (DP) have been described in the literature. Initially described in younger patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/1-5\">",
"     1-5",
"    </a>",
"    ], subsequent publications have reported that DP also occurs in older individuals (up to 79 years old) with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of DP is uncertain. A diabetic microangiopathy has been proposed as an etiology, but no pathologic studies of DP have been reported to confirm or refute this theory. There is no clear association between DP and the state of metabolic control of the diabetes or with the stage of diabetic retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. Most reported cases of DP occur in patients with long-standing diabetes, but duration of diabetes is not proven to be a risk factor for DP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/2,3,5,7\">",
"     2,3,5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most authors appear to believe that DP represents a mild form of nonarteritic anterior ischemic optic neuropathy (NAION) with reversible ischemia of the prelaminar and inner surface layer of the optic nerve head [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. The following observations support this theory:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes is a risk factor for NAION as well as DP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20442?source=see_link\">",
"       \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The small optic cup or crowded optic nerve head (the so-called \"disc-at-risk\") is frequently seen in the fellow eye in both DP and NAION [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/6,8,10,11\">",
"       6,8,10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients may develop both DP and NAION [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/8,11,12\">",
"       8,11,12",
"      </a>",
"      ]. Patients with NAION may demonstrate asymptomatic disc edema in the fellow eye either at presentation or in follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/12\">",
"       12",
"      </a>",
"      ]. In one series, 43 percent of patients with DP had a history of NAION in the other eye [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients with DP develop irreversible visual loss and optic disc pallor similar to NAION [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/4\">",
"       4",
"      </a>",
"      ]. Approximately 30 percent develop NAION in the same or fellow eye in follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/11,13\">",
"       11,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One author described an entity of so-called incipient NAION (ie, disc edema without significant visual loss) in 54 patients who were seen in follow-up after a previous episode of NAION in the other eye or for unrelated conditions (eg, diabetic retinopathy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/12\">",
"     12",
"    </a>",
"    ]. In this series, 63 percent of patients were diabetic and therefore met the usual clinical definition of DP. Perhaps somewhat atypical was that just 11 percent of these patients had bilateral disease. A high proportion of these patients, 45 percent, went on to develop NAION in that eye [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arguments that support a pathogenesis for DP distinct from that of NAION include the observation that disc edema persists longer in DP than in NAION. While disc edema usually resolves by two to three months in NAION, a duration of 10 months or more is not unusual in DP. DP is also more frequently bilateral at presentation than NAION, and is more often described in younger age groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/9,14\">",
"     9,14",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical features'",
"    </a>",
"    below). Despite these qualitative differences, there is substantial overlap in the clinical features of DP and NAION [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One author proposes that diabetes influences the course of NAION in a manner that explains the apparent clinical differences between NAION and DP. In their experience, patients with NAION and diabetes had several distinct clinical and demographic features that were distinct from patients with NAION without diabetes, including a longer duration of disc edema and a better final visual prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/15\">",
"     15",
"    </a>",
"    ]. However, it can be argued that this case series used a more inclusive definition of NAION that included patients who others might have labeled as DP and not NAION, making their argument somewhat circular.",
"   </p>",
"   <p>",
"    Some hypothesize that the pathogenesis of diabetic papillopathy may be similar to the phenomena of early worsening of diabetic retinopathy sometimes observed after metabolic control ensues. In a study of 2066 patients with type 1 diabetes followed for a mean of 4.85 years (10,020 patient-years), bilateral diabetic papillopathy developed in five patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/16\">",
"     16",
"    </a>",
"    ]. During the year preceding this incident, all five patients had experienced a decrease in glycosylated hemoglobin A",
"    <sub>",
"     1c",
"    </sub>",
"    at a maximum rate of &ndash;2.5 percentage points per quarter year, which was significantly different from the changes observed in the remainder of the study population. Photographs recorded before the onset of bilateral diabetic papillopathy showed that all five patients had small cup-to-disc diameter ratios in both eyes. Limitations of the study include its retrospective design and the low frequency of events.",
"   </p>",
"   <p>",
"    An alternative theory for DP proposes that it is a distinct form of diabetic microangiopathy that primarily affects capillary integrity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/8\">",
"     8",
"    </a>",
"    ]. However, this is speculative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Visual loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DP typically present with nonspecific visual complaints such as mild blurring or distortion of vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/5\">",
"     5",
"    </a>",
"    ]. Alternatively, DP may be an incidental (asymptomatic) finding on routine ophthalmologic examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/7,11\">",
"     7,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Visual acuity is often normal or only mildly abnormal. When abnormal, acuity deficits are usually explained by comorbid pathology including diabetic retinopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    macular edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. Associated macular edema is usually related to diabetic retinopathy. Visual fields may be normal or demonstrate a slightly enlarged blind spot; other visual field deficits usually reflect comorbid pathology rather than DP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Funduscopic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Funduscopic examination demonstrates optic disc swelling, often with hyperemia and a striking dilation of the inner optic disc vasculature (",
"    <a class=\"graphic graphic_picture graphicRef63843 \" href=\"mobipreview.htm?37/29/38367\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. The surface telangiectasia may be so prominent in some patients that it can be mistaken for neovascularization of the optic disc. One difference is that the vessels on the optic disc are radially distributed in DP as opposed to the random branching pattern of neovascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/17\">",
"     17",
"    </a>",
"    ]. The abnormal-appearing vessels are limited to the disc surface and do not protrude into the vitreous cavity. This finding is also useful to distinguish DP from neovascularization of the disc.",
"   </p>",
"   <p>",
"    The optic disc edema may be unilateral or bilateral; when bilateral, the involvement may be simultaneous or sequential. Various studies report that a bilateral presentation occurs in 11 to 60 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/3,7,11,12\">",
"     3,7,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Macular edema is a frequent comorbid finding, occurring in 70 to 100 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/6,18,19\">",
"     6,18,19",
"    </a>",
"    ]. The etiology of macular edema may be related to breakdown of blood-retinal barrier and leakage from retinal capillaries. However, serous macular detachment has been described in three patients with diabetic papillopathy occurring as a result of capillary leakage from the swollen optic nerve head in the absence of retinal capillary leakage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other manifestations of diabetic retinopathy, usually nonproliferative diabetic retinopathy, are seen in either the involved or unaffected eye in 35 to 90 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/7\">",
"     7",
"    </a>",
"    ]. Examination of the fellow eye usually reveals a small optic disc cup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=see_link\">",
"     \"Classification and clinical features of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optic disc findings resolve spontaneously in follow-up examinations; the reported mean duration of findings has varied in small studies between four and eight months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The optic disc then appears normal, only rarely demonstrating mild optic neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fluorescein angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     Fluorescein",
"    </a>",
"    angiography usually demonstrates disc staining in patients with DP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/11,19\">",
"     11,19",
"    </a>",
"    ]. The dye leakage into the disc substance and peripapillary retina seen in DP contrasts with leakage anteriorly into the vitreous that occurs from neovascular tissue in patients with proliferative diabetic retinopathy. Fluorescein angiography also more clearly demonstrates the radial pattern of dilated vessels that is typical of DP and helps distinguish it from neovascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/17\">",
"     17",
"    </a>",
"    ]. Capillary nonperfusion is variably seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. A less common finding in DP is a delay in filling that is similar to that seen in NAION [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic papillopathy is a diagnosis of exclusion; other entities such as papilledema, optic disc neovascularization, malignant hypertension, papillitis, and NAION need to be considered in the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef54401 \" href=\"mobipreview.htm?21/28/21963\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30552?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview and differential diagnosis of papilledema\", section on 'Differential Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because diabetic papillopathy is a diagnosis of exclusion, diagnostic testing is usually required. When the disc edema is bilateral, papilledema secondary to increased intracranial pressure is a potentially life-threatening cause and neuroimaging, usually with magnetic resonance imaging (MRI), followed by a lumbar puncture (LP) if the MRI is normal should proceed expeditiously. Patients with unilateral disc edema and other clinical and test features that are consistent with DP may not require MRI or LP. Ophthalmologic evaluation with visual field testing and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography can be helpful in excluding other causes and providing confirmatory evidence of DP. Patients should have ophthalmologic follow-up to monitor for vision loss and confirm the expected resolution of the disc edema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30552?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview and differential diagnosis of papilledema\", section on 'Diagnostic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because DP produces mild or no visual loss, the prognosis is understood to be benign. However, some patients with a presentation consistent with DP develop vision loss over the next few weeks, either because of progression to NAION, worsening macular edema, or progression of diabetic retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/11,21,22\">",
"     11,21,22",
"    </a>",
"    ]. In one series that included 19 diabetic patients with asymptomatic disc edema, NAION developed in 30 percent over a few weeks to a few months, as well as in an additional patient at 80 weeks, after the initial presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/11\">",
"     11",
"    </a>",
"    ]. In this series, the presence of retinopathy or a previous episode of NAION in the fellow eye did not affect the incidence of NAION. Similarly, DP does not appear to influence the progression of the underlying diabetic retinopathy, although this does occur in up to 25 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/3,7,21\">",
"     3,7,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, no treatment is required or recommended for patients with DP. Patients should be followed to confirm the expected resolution of the optic disc findings and to monitor for vision loss.",
"   </p>",
"   <p>",
"    Some clinicians advocate the routine use of corticosteroids in patients with DP to ameliorate progression to NAION and or clinically significant macular edema. However, in one observational cohort, oral corticosteroid therapy did not influence progression to NAION [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/12\">",
"     12",
"    </a>",
"    ]. The use of intravitreal and periocular (sub-tenon) injection of steroids has been reported in a small number of patients who developed severe optic nerve dysfunction from either the papillopathy or macular edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/18,22\">",
"     18,22",
"    </a>",
"    ]. These patients subsequently had substantial and rapid resolution of both disc and macular edema, as well as visual function after treatment. Intravitreal steroid therapy is also a treatment option for macular edema associated with diabetic retinopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link&amp;anchor=H3693387#H3693387\">",
"     \"Prevention and treatment of diabetic retinopathy\", section on 'Intravitreal glucocorticoids for ME'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few case reports have noted resolution of disc swelling and macular edema, along with significant improvement in visual acuity after single intravitreal injection of a vascular endothelial growth factor inhibitor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    ) was associated with significant improvement in vision in a 43-year-old woman with significant vision loss attributed to diabetic papillopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/23\">",
"     23",
"    </a>",
"    ]. In one case, marked clinical resolution occurred only in the one eye injected, suggesting that the treatment altered the natural course of the condition, and that vascular endothelial growth factor may be involved in the pathogenesis of diabetic papillopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44293/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic papillopathy (DP) is a term that is usually used to characterize a finding of unilateral or bilateral optic disc edema with mild or no visual loss in a patient with diabetes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DP is associated with type 1 and type 2 diabetes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DP likely represents a mild form of nonarteritic anterior ischemic optic neuropathy, although this is not certain. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DP usually presents with very mild vision loss or as an incidental finding of unilateral or bilateral optic disc edema. Macular edema and other features of diabetic retinopathy are common findings. A small optic disc cup in the fellow eye is also usual. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DP is a diagnosis of exclusion. Increased intracranial pressure and other causes of optic disc swelling must be excluded. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Up to 30 percent of patients with DP may develop subsequent vision loss from NAION or from macular edema or other forms of diabetic retinopathy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No treatment is required for uncomplicated DP or is known to prevent subsequent vision loss from either NAION or diabetic retinopathy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/1\">",
"      Lubow M, Makley TA Jr. Pseudopapilledema of juvenile diabetes mellitus. Arch Ophthalmol 1971; 85:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/2\">",
"      Appen RE, Chandra SR, Klein R, Myers FL. Diabetic papillopathy. Am J Ophthalmol 1980; 90:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/3\">",
"      Barr CC, Glaser JS, Blankenship G. Acute disc swelling in juvenile diabetes. Clinical profile and natural history of 12 cases. Arch Ophthalmol 1980; 98:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/4\">",
"      Hayreh SS, Zahoruk RM. Anterior ischemic optic neuropathy. VI. In juvenile diabetics. Ophthalmologica 1981; 182:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/5\">",
"      Pavan PR, Aiello LM, Wafai MZ, et al. Optic disc edema in juvenile-onset diabetes. Arch Ophthalmol 1980; 98:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/6\">",
"      Regillo CD, Brown GC, Savino PJ, et al. Diabetic papillopathy. Patient characteristics and fundus findings. Arch Ophthalmol 1995; 113:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/7\">",
"      Bayraktar Z, Alacali N, Bayraktar S. Diabetic papillopathy in type II diabetic patients. Retina 2002; 22:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/8\">",
"      Inoue M, Tsukahara Y. Vascular optic neuropathy in diabetes mellitus. Jpn J Ophthalmol 1997; 41:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/9\">",
"      Hayreh SS. Diabetic papillopathy and nonarteritic anterior ischemic optic neuropathy. Surv Ophthalmol 2002; 47:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/10\">",
"      Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1996; 114:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/11\">",
"      Almog Y, Goldstein M. Visual outcome in eyes with asymptomatic optic disc edema. J Neuroophthalmol 2003; 23:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/12\">",
"      Hayreh SS, Zimmerman MB. Incipient nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2007; 114:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/13\">",
"      Sato T, Fujikado T, Hosohata J, et al. Development of bilateral, nonarteritic anterior ischemic optic neuropathy in an eye with diabetic papillopathy. Jpn J Ophthalmol 2004; 48:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/14\">",
"      Wu GF, Balcer LJ. Endocrine and metabolic deficiency. Ophthalmol Clin North Am 2004; 17:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/15\">",
"      Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: clinical characteristics in diabetic patients versus nondiabetic patients. Ophthalmology 2008; 115:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/16\">",
"      Ostri C, Lund-Andersen H, Sander B, et al. Bilateral diabetic papillopathy and metabolic control. Ophthalmology 2010; 117:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/17\">",
"      Vaphiades MS. The disk edema dilemma. Surv Ophthalmol 2002; 47:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/18\">",
"      Mansour AM, El-Dairi MA, Shehab MA, et al. Periocular corticosteroids in diabetic papillopathy. Eye (Lond) 2005; 19:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/19\">",
"      Friedrich Y, Feiner M, Gawi H, Friedman Z. Diabetic papillopathy with macular star mimicking clinically significant diabetic macular edema. Retina 2001; 21:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/20\">",
"      Nakamura M, Kanamori A, Nagai-Kusuhara A, et al. Serous macular detachment due to diabetic papillopathy detected using optical coherence tomography. Arch Ophthalmol 2009; 127:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/21\">",
"      Ho AC, Maguire AM, Yannuzzi LA, et al. Rapidly progressive optic disk neovascularization after diabetic papillopathy. Am J Ophthalmol 1995; 120:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/22\">",
"      Al-Haddad CE, Jurdi FA, Bashshur ZF. Intravitreal triamcinolone acetonide for the management of diabetic papillopathy. Am J Ophthalmol 2004; 137:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/23\">",
"      Ornek K, O��urel T. Intravitreal bevacizumab for diabetic papillopathy. J Ocul Pharmacol Ther 2010; 26:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44293/abstract/24\">",
"      Al-Dhibi H, Khan AO. Response of diabetic papillopathy to intravitreal bevacizumab. Middle East Afr J Ophthalmol 2011; 18:243.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5235 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44293=[""].join("\n");
var outline_f43_16_44293=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Visual loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Funduscopic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fluorescein angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5235\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5235|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/29/38367\" title=\"picture 1\">",
"      Diabetic papillopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5235|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/28/21963\" title=\"table 1\">",
"      Differential diagnosis of papilledema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=related_link\">",
"      Classification and clinical features of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27558?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20442?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/44/9929?source=related_link\">",
"      Nonarteritic ischemic optic neuropathy: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30552?source=related_link\">",
"      Overview and differential diagnosis of papilledema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_16_44294="Pegylated interferon (peginterferon) alfa-2a and ribavirin: Patient drug information";
var content_f43_16_44294=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pegylated interferon (peginterferon) alfa-2a and ribavirin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1272?source=see_link\">",
"     see \"Pegylated interferon (peginterferon) alfa-2a and ribavirin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9491710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pegasys&reg; RBV",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692178",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This product is made up of 2 drugs, ribavirin and peginterferon alfa-2a. They are used at the same time to treat some patients with hepatitis C infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705230",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to peginterferon alfa-2a, ribavirin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Autoimmune disease, autoimmune hepatitis, liver disease, some types of anemia, uncontrolled thyroid disease, or very bad mental disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701069",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are of childbearing age, but are not using 2 kinds of birth control or if you are planning to get pregnant during your care or within 6 months after care has ended.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with a sex partner who is pregnant or plans on getting pregnant at any time while you are being treated or within 6 months after your care has ended.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703869",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have used interferon before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been treated for hepatitis C infection before with this drug and it did not work, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697192",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have cancer, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697263",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hepatitis B or HIV disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks. Alcohol may make liver disease worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 2 kinds of birth control that you can trust while using this drug and for 6 months after stopping this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy during care and for 6 months after care ends. Use 2 kinds of birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair thinning.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark, tarry-black stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698669",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug or within 6 months after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698676",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For men, if your woman partner gets pregnant while you are being treated or within 6 months after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, take a monthly pregnancy test.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ribavirin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Peginterferon alfa-2b:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime to help with flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw syringe away after use. Do not use more than one time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699534",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store ribavirin in a refrigerator or at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store peginterferon in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not shake.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12281 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44294=[""].join("\n");
var outline_f43_16_44294=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9491710\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028110\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028112\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028111\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028116\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028117\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028119\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028114\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028115\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028120\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028121\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1272?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2a and ribavirin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_16_44295="Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state";
var content_f43_16_44295=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/16/44295/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44295/contributors\">",
"     Abbas E Kitabchi, PhD, MD, FACP, FACE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/16/44295/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44295/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44295/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/16/44295/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44295/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/16/44295/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS, also called nonketotic hyperglycemia) are two of the most serious acute complications of diabetes. They are part of the spectrum of hyperglycemia and each represents an extreme in the spectrum.",
"   </p>",
"   <p>",
"    The epidemiology and pathogenesis of DKA and HHS will be discussed here. The clinical features, diagnosis, and treatment of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/48/15114?source=see_link\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic ketoacidosis is characteristically associated with type 1 diabetes. It also occurs in type 2 diabetes under conditions of extreme stress such as serious infection, trauma, cardiovascular or other emergencies, and, less often, as a presenting manifestation of type 2 diabetes, a disorder called ketosis-prone diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32920?source=see_link\">",
"     \"Syndromes of ketosis-prone diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DKA is more common in young (&lt;65 years) diabetic patients and in women compared to men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The National Diabetes Surveillance Program of the Centers for Disease Control (CDC) estimated that there were 120,000 hospital discharges for DKA in 2005 in the United States, compared to 62,000 in 1980 (",
"    <a class=\"graphic graphic_figure graphicRef73971 \" href=\"mobipreview.htm?34/37/35422\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/4\">",
"     4",
"    </a>",
"    ]. On the other hand, DKA mortality per 100,000 diabetic patients declined between 1985 and 2005 with the greatest reduction in mortality among those 65 years of age and older (",
"    <a class=\"graphic graphic_figure graphicRef68391 \" href=\"mobipreview.htm?32/8/32909\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/5\">",
"     5",
"    </a>",
"    ]. Mortality in DKA is primarily due to the underlying precipitating illness and only rarely to the metabolic complications of hyperglycemia or ketoacidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/1\">",
"     1",
"    </a>",
"    ]. The prognosis of DKA is substantially worse at the extremes of age and in the presence of coma and hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Population-based data are not available for HHS. It is estimated that the rate of hospital admissions for HHS is lower than the rate for DKA, and accounts for less than 1 percent of all primary diabetic admissions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/1,10-12\">",
"     1,10-12",
"    </a>",
"    ]. HHS is most commonly seen in individuals older than 65 years with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. Mortality attributed to HHS is higher than that of DKA, with rates ranging from 5 to 20 percent; as in DKA, mortality is most often due to the underlying illness or comorbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/1,3,10,11,13,14\">",
"     1,3,10,11,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two hormonal abnormalities are largely responsible for the development of hyperglycemia and ketoacidosis in patients with uncontrolled diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulin deficiency",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      resistance.",
"     </li>",
"     <li>",
"      Glucagon excess, which may result from removal of the normal suppressive effect of insulin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. There is no evidence for defective pancreatic alpha cell function in diabetes, since there is a normal glucagon response to nonhypoglycemic stimuli, such as arginine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although glucagon excess contributes to the development of DKA, it is not required. As an example, patients with complete pancreatectomies and who have no pancreatic glucagon will develop DKA if insulin is withheld; however, it takes longer for DKA to develop compared with patients with type 1 diabetes.",
"   </p>",
"   <p>",
"    In addition to these primary factors, increased secretion of catecholamines and cortisol can contribute to the increases in glucose and ketoacid production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Normal response to hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hormonal regulation of glucose homeostasis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41702?source=see_link\">",
"     \"Insulin secretion and pancreatic beta-cell function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25511?source=see_link\">",
"     \"Insulin action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29638?source=see_link\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, the extracellular supply of glucose is primarily regulated by two hormones: insulin and glucagon. As the serum glucose concentration rises after a glucose meal, glucose enters the pancreatic beta cells, initiating a sequence of events leading to insulin release.",
"   </p>",
"   <p>",
"    Insulin acts to restore normoglycemia by diminishing hepatic glucose production, via reductions in both glycogenolysis and gluconeogenesis, and by increasing glucose uptake by skeletal muscle and adipose tissue. Insulin-induced inhibition of glucagon secretion contributes to the decline in hepatic glucose production; this effect is mediated by direct inhibition of glucagon secretion and of the glucagon gene in the pancreatic alpha cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/16,17,20\">",
"     16,17,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Precipitating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both DKA and HHS are usually precipitated by stresses that act in part by increasing the secretion of glucagon, catecholamines, and cortisol. Infection, such as pneumonia, gastroenteritis, and urinary tract infection, can be found in 40 to 50 percent of patients with hyperglycemic crisis; other stresses include pancreatitis, myocardial infarction, stroke, trauma, and alcohol and drug abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mistaken omission of insulin in the setting of an acute illness, especially with gastroenteritis, failure to appropriately augment insulin, and dehydration with inability to replenish water intake, are common precipitants of a hyperglycemic crisis (",
"    <a class=\"graphic graphic_table graphicRef64374 \" href=\"mobipreview.htm?35/22/36205\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Precipitating factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Spectrum of hyperglycemic crises",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic mechanism underlying both DKA and HHS is reduction in the net effective action of circulating insulin, with concomitant elevation of counterregulatory hormones, primarily glucagon, but also catecholamines, cortisol, and growth hormone (",
"    <a class=\"graphic graphic_algorithm graphicRef78145 \" href=\"mobipreview.htm?42/34/43567\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/1,7-9,13,15,17-19,24-27\">",
"     1,7-9,13,15,17-19,24-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The deficiency in insulin (absolute deficiency, or relative to excess counterregulatory hormones) is more severe in DKA compared with HHS. The residual insulin secretion in HHS is sufficient to minimize ketosis but does not control hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DKA and HHS are two extremes in the spectrum of hyperglycemic crisis and patients can fall anywhere along the disease continuum of diabetic metabolic derangement (",
"    <a class=\"graphic graphic_table graphicRef72111 \" href=\"mobipreview.htm?24/19/24892\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum glucose concentration in HHS frequently exceeds 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (56",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    but in DKA is generally below 800",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least two factors contribute to the lesser degree of hyperglycemia in DKA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with DKA often present early with symptoms of ketoacidosis (such as shortness of breath and abdominal pain), rather than late with symptoms due to hyperosmolality.",
"     </li>",
"     <li>",
"      Patients with DKA tend to be young and to have a glomerular filtration rate that, at least in the first five years of diabetes, may be as much as 50 percent above normal. As a result, they have a much greater capacity to excrete glucose than the usually older patients with HHS, thereby limiting the degree of hyperglycemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=see_link\">",
"       \"Overview of diabetic nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal alterations in DKA and HHS result in hyperglycemia by their impact on three fundamental processes in glucose metabolism (",
"    <a class=\"graphic graphic_algorithm graphicRef78145 \" href=\"mobipreview.htm?42/34/43567\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/1,8,9,24,26-28,30-32\">",
"     1,8,9,24,26-28,30-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired glucose utilization in peripheral tissues",
"     </li>",
"     <li>",
"      Increased gluconeogenesis (both hepatic and renal)",
"     </li>",
"     <li>",
"      Increased glycogenolysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insulin deficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resistance in diabetic patients impair peripheral glucose utilization in skeletal muscle. However, decreased glucose utilization alone will produce only postprandial hyperglycemia; increased gluconeogenesis is required for the often severe fasting hyperglycemia seen in DKA and HHS.",
"   </p>",
"   <p>",
"    Insulin deficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resistance promote hepatic gluconeogenesis by two mechanisms: increased delivery of gluconeogenetic precursors (glycerol and alanine) to the liver due to increased fat and muscle breakdown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/15,33,34\">",
"     15,33,34",
"    </a>",
"    ]; and increased secretion of glucagon by removal of the inhibitory effect of insulin on glucagon secretion and the glucagon gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/16,17,20,35\">",
"     16,17,20,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of glucagon in the development of hyperglycemia and ketoacidosis in uncontrolled diabetes has been demonstrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After discontinuing insulin in a patient with type 1 diabetes, the rate of rise in serum glucose can be markedly attenuated if glucagon release is prevented by infusing somatostatin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The magnitude of this effect is illustrated by studies in patients who have undergone total pancreatectomy who make neither insulin nor glucagon. In one report, four such patients and six with type 1 diabetes were fasted after having been maintained on intravenous insulin for 24 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/36\">",
"       36",
"      </a>",
"      ]. After withdrawal of insulin, there was a sharp increase in serum glucagon in the patients with type 1 diabetes. Compared with the pancreatectomized patients, these patients had significantly greater increases in blood glucose (225 versus 139",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [12.5 versus 7.7",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and blood ketone concentration (4.1 versus 1.8",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      at 12 hours. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ketoacidosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The glucosuria associated with DKA and HHS initially minimizes the rise in serum glucose. However, the osmotic diuresis caused by glucosuria leads to volume depletion and a reduction in glomerular filtration rate that limits further glucose excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/14,29,31,32\">",
"     14,29,31,32",
"    </a>",
"    ]. This effect is more pronounced in HHS which, as noted above, is usually associated with a higher serum glucose than seen in DKA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Spectrum of hyperglycemic crises'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Importance of osmotic diuresis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Ketoacidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both insulin deficiency and glucagon excess contribute to the genesis of DKA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/33,36,37\">",
"     33,36,37",
"    </a>",
"    ]. As noted above, however, glucagon is not required for DKA to occur.",
"   </p>",
"   <p>",
"    Acetoacetic acid is the initial ketone formed; it may then be reduced to beta-hydroxybutyric acid, which is also an organic acid, or nonenzymatically decarboxylated to acetone, which is chemically neutral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/38\">",
"     38",
"    </a>",
"    ]. Ketones provide an alternate source of energy when glucose utilization is impaired.",
"   </p>",
"   <p>",
"    Insulin deficiency and increased catecholamine lead to enhanced lipolysis, thereby increasing free fatty acid delivery to the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/15,33,37\">",
"     15,33,37",
"    </a>",
"    ]. Normal subjects will convert these free fatty acids primarily into triglycerides. The development of ketoacidosis requires a specific alteration in hepatic metabolism so that free fatty acyl CoA can enter the mitochondria, where conversion to ketones occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/15,33\">",
"     15,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mitochondrial entry is regulated by the cytosolic enzyme",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    palmitoyltransferase I (CPT I), the activity of which varies inversely with malonyl CoA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/33,39-41\">",
"     33,39-41",
"    </a>",
"    ]. Glucagon decreases the production of malonyl CoA, thereby increasing CPT I activity and ketogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/33,42\">",
"     33,42",
"    </a>",
"    ]. A concurrent increase in hepatic carnitine content contributes to this process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/43\">",
"     43",
"    </a>",
"    ]. Insulin does not appear to directly affect hepatic ketogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In states of insulin deficiency, the combination of increased free fatty acid delivery and glucagon excess promotes ketogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/37\">",
"     37",
"    </a>",
"    ]. In the study comparing pancreatectomized and type 1 diabetic patients cited above, there was a marked increase in serum glucagon after insulin withdrawal in the patients with type 1 diabetes, associated with a significantly increased blood ketone concentration at 12 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factors responsible for the general absence of ketoacidosis in HHS are incompletely understood. One important factor may be the differential sensitivity of fat and glucose to the effects of insulin. Studies in humans have demonstrated that the concentration of insulin required to suppress lipolysis is only one-tenth that required to promote glucose utilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/44\">",
"     44",
"    </a>",
"    ]. Thus, moderate insulin deficiency, as seen in HHS, might be associated with sufficient insulin to block lipolysis (and therefore ketoacid formation) but not enough to promote glucose utilization and prevent the development of hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/30\">",
"     30",
"    </a>",
"    ]. More severe insulin deficiency will also be associated with ketoacidosis.",
"   </p>",
"   <p>",
"    There are several observations compatible with this general hypothesis. DKA tends to occur in patients with type 1 diabetes, who produce little or no insulin. HHS, in comparison, is found primarily in older patients with type 2 diabetes, who have decreased but not absent insulin effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/15,28,45\">",
"     15,28,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this distinction is not absolute since DKA can occur in patients with type 2 diabetes. This most often occurs in obese African Americans, but has also been described in Caucasians, Hispanics, and other populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32920?source=see_link\">",
"     \"Syndromes of ketosis-prone diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemic crises are proinflammatory states that lead to generation of reactive oxygen species, which are indicators of oxidative stress. Studies have shown elevation of the pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin (IL)-1B, IL-6, and IL-8 and lipid peroxidation markers, as well as plasminogen activator inhibitor-1 and C-reactive protein (CRP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/47\">",
"     47",
"    </a>",
"    ]. Proinflammatory factors returned to near normal levels within 24 hours of insulin therapy and remission of hyperglycemia. The proinflammatory state in DKA results in in vivo activation of T-lymphocytes with de novo emergence of growth factor receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44295/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/6/25699?source=see_link\">",
"       \"Patient information: Hyperosmolar nonketotic coma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are part of a spectrum, representing the metabolic consequences of insulin deficiency, glucagon excess, and counterregulatory hormonal responses to stressful triggers in patients with diabetes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DKA is more common in younger patients with type 1 diabetes, though it can occur in type 2 diabetes. HHS occurs less frequently, and is associated with higher mortality, representing underlying comorbidity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperglycemia results from impaired glucose utilization, increased gluconeogenesis and increased glycogenolysis (",
"      <a class=\"graphic graphic_algorithm graphicRef78145 \" href=\"mobipreview.htm?42/34/43567\">",
"       algorithm 1",
"      </a>",
"      ). Gluconeogenesis results from delivery of precursors to the liver from breakdown of fat and muscle, and is promoted by insulin deficiency and glucagon excess. Glycogenolysis is stimulated by catecholamines and a high glucagon to insulin ratio. Osmotic diuresis further contributes to elevated blood glucose. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hyperglycemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucose concentrations are most often lower (usually &lt;800",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [44",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      in DKA compared with HHS. Patients with DKA present earlier, because of symptoms, and generally can excrete glucose more effectively than older patients with HHS. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Spectrum of hyperglycemic crises'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ketoacidosis results from lipolysis, with synthesis of ketones from free fatty acids in the liver mitochondria. Insulin levels in HHS are insufficient to allow appropriate glucose utilization, but are adequate to prevent lipolysis and subsequent ketogenesis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ketoacidosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/1\">",
"      Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care 2001; 24:131.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. National hospital discharge survey. www.cdc.gov/nchs/nhds.htm (Accessed on August 16, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/3\">",
"      Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32:1335.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/diabetes/statistics/hospitalization_national.htm (Accessed on March 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/5\">",
"      Wang J, Williams DE, Narayan KM, Geiss LS. Declining death rates from hyperglycemic crisis among adults with diabetes, U.S., 1985-2002. Diabetes Care 2006; 29:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/6\">",
"      Kreisberg RA. Diabetic ketoacidosis: an update. Crit Care Clin 1987; 3:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/7\">",
"      Malone ML, Gennis V, Goodwin JS. Characteristics of diabetic ketoacidosis in older versus younger adults. J Am Geriatr Soc 1992; 40:1100.",
"     </a>",
"    </li>",
"    <li>",
"     Kitabchi AE, Umpierrez GE, Murphy MB. Diabetic ketoacidosis and hyperglycemic hypersmolar state. In: International Textbook of Diabetes Mellitus, 3rd, DeFronzo RA, Ferrannini E, Keen H, Zimmet P (Eds), John Wiley &amp; Sons, Chichester, UK 2004. p.1101.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/9\">",
"      Wachtel TJ, Silliman RA, Lamberton P. Prognostic factors in the diabetic hyperosmolar state. J Am Geriatr Soc 1987; 35:737.",
"     </a>",
"    </li>",
"    <li>",
"     Fishbein, HA, Palumbo, PJ. Acute metabolic complications in diabetes. In: Diabetes in America. National Diabetes Data Group, National Institutes of Health, 1995, p. 283 (NIH publ. no: 95-1468).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/11\">",
"      Umpierrez GE, Kelly JP, Navarrete JE, et al. Hyperglycemic crises in urban blacks. Arch Intern Med 1997; 157:669.",
"     </a>",
"    </li>",
"    <li>",
"     Kitabchi AE, Fisher JN, Murphy MB, Rumbak MJ. Diabetic ketoacidosis and the hyperglycemic hyperosmolar nonketotic state. In: Joslin's Diabetes Mellitus, 13th, Kahn CR, Weir GC (Eds), Lea &amp; Febiger, Philadelphia 1994. p.738.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/13\">",
"      Ennis, ED, Stahl, EJVB, Kreisberg, RA. The hyperosmolar hyperglycemic syndrome. Diabetes Rev 1994; 2:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/14\">",
"      Lorber D. Nonketotic hypertonicity in diabetes mellitus. Med Clin North Am 1995; 79:39.",
"     </a>",
"    </li>",
"    <li>",
"     Rose BD, Post TW. Clinical physiology of acid-base and electrolyte disorders, 5th, McGraw-Hill, New York 2001. p.794.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/16\">",
"      Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med 1981; 304:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/17\">",
"      Diamond MP, Hallarman L, Starick-Zych K, et al. Suppression of counterregulatory hormone response to hypoglycemia by insulin per se. J Clin Endocrinol Metab 1991; 72:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/18\">",
"      Josefsberg Z, Laron Z, Doron M, et al. Plasma glucagon response to arginine infusion in children and adolescents with diabetes mellitus. Clin Endocrinol (Oxf) 1975; 4:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/19\">",
"      Palmer JP, Benson JW, Walter RM, Ensinck JW. Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects. J Clin Invest 1976; 58:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/20\">",
"      Philippe J. Insulin regulation of the glucagon gene is mediated by an insulin-responsive DNA element. Proc Natl Acad Sci U S A 1991; 88:7224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/21\">",
"      Kitabchi AE, Umpierrez GE, Murphy MB, et al. Hyperglycemic crises in patients with diabetes mellitus. Diabetes Care 2003; 26 Suppl 1:S109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/22\">",
"      Nyenwe EA, Loganathan RS, Blum S, et al. Active use of cocaine: an independent risk factor for recurrent diabetic ketoacidosis in a city hospital. Endocr Pract 2007; 13:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/23\">",
"      Warner EA, Greene GS, Buchsbaum MS, et al. Diabetic ketoacidosis associated with cocaine use. Arch Intern Med 1998; 158:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/24\">",
"      DeFronzo, RA, Matzuda, M, Barret, E. Diabetic ketoacidosis: a combined metabolic-nephrologic approach to therapy. Diabetes Rev 1994; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/25\">",
"      Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, et al. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med 1991; 6:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/26\">",
"      Wachtel TJ. The diabetic hyperosmolar state. Clin Geriatr Med 1990; 6:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/27\">",
"      Gerich JE, Martin MM, Recant L. Clinical and metabolic characteristics of hyperosmolar nonketotic coma. Diabetes 1971; 20:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/28\">",
"      Chupin M, Charbonnel B, Chupin F. C-peptide blood levels in keto-acidosis and in hyperosmolar non-ketotic diabetic coma. Acta Diabetol Lat 1981; 18:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/29\">",
"      Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases. Medicine (Baltimore) 1972; 51:73.",
"     </a>",
"    </li>",
"    <li>",
"     Kitabchi AE, Fisher JN. Insulin therapy of diabetic ketoacidosis: Physiologic versus pharmacologic doses of insulin and their routes of administration. In: Handbook of Diabetes Mellitus, Brownlee M (Ed), Garland ATPM, New York 1981. p.95.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/31\">",
"      Hillman K. Fluid resuscitation in diabetic emergencies--a reappraisal. Intensive Care Med 1987; 13:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/32\">",
"      Delaney MF, Zisman A, Kettyle WM. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin North Am 2000; 29:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/33\">",
"      Foster DW. Banting lecture 1984. From glycogen to ketones--and back. Diabetes 1984; 33:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/34\">",
"      Sacc&agrave; L, Orofino G, Petrone A, Vigorito C. Differential roles of splanchnic and peripheral tissues in the pathogenesis of impaired glucose tolerance. J Clin Invest 1984; 73:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/35\">",
"      Pilkis SJ, el-Maghrabi MR, Claus TH. Fructose-2,6-bisphosphate in control of hepatic gluconeogenesis. From metabolites to molecular genetics. Diabetes Care 1990; 13:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/36\">",
"      Barnes AJ, Bloom SR, Goerge K, et al. Ketoacidosis in pancreatectomized man. N Engl J Med 1977; 296:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/37\">",
"      Miles JM, Haymond MW, Nissen SL, Gerich JE. Effects of free fatty acid availability, glucagon excess, and insulin deficiency on ketone body production in postabsorptive man. J Clin Invest 1983; 71:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/38\">",
"      Owen OE, Trapp VE, Skutches CL, et al. Acetone metabolism during diabetic ketoacidosis. Diabetes 1982; 31:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/39\">",
"      McGarry JD, Mannaerts GP, Foster DW. A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest 1977; 60:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/40\">",
"      Declercq PE, Falck JR, Kuwajima M, et al. Characterization of the mitochondrial carnitine palmitoyltransferase enzyme system. I. Use of inhibitors. J Biol Chem 1987; 262:9812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/41\">",
"      McGarry JD, Woeltje KF, Kuwajima M, Foster DW. Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. Diabetes Metab Rev 1989; 5:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/42\">",
"      Cook GA, Nielsen RC, Hawkins RA, et al. Effect of glucagon on hepatic malonyl coenzyme A concentration and on lipid synthesis. J Biol Chem 1977; 252:4421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/43\">",
"      McGarry JD, Robles-Valdes C, Foster DW. Role of carnitine in hepatic ketogenesis. Proc Natl Acad Sci U S A 1975; 72:4385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/44\">",
"      ZIERLER KL, RABINOWITZ D. EFFECT OF VERY SMALL CONCENTRATIONS OF INSULIN ON FOREARM METABOLISM. PERSISTENCE OF ITS ACTION ON POTASSIUM AND FREE FATTY ACIDS WITHOUT ITS EFFECT ON GLUCOSE. J Clin Invest 1964; 43:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/45\">",
"      Khardori R, Soler NG. Hyperosmolar hyperglycemic nonketotic syndrome. Report of 22 cases and brief review. Am J Med 1984; 77:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/46\">",
"      Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med 2006; 144:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/47\">",
"      Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004; 53:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44295/abstract/48\">",
"      Kitabchi AE, Stentz FB, Umpierrez GE. Diabetic ketoacidosis induces in vivo activation of human T-lymphocytes. Biochem Biophys Res Commun 2004; 315:404.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1794 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44295=[""].join("\n");
var outline_f43_16_44295=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Normal response to hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Precipitating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Spectrum of hyperglycemic crises",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1794\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1794|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?42/34/43567\" title=\"algorithm 1\">",
"      Pathogenesis DKA and HHS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1794|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/37/35422\" title=\"figure 1\">",
"      Number of hospital discharges with diabetic ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/8/32909\" title=\"figure 2\">",
"      Age-adjusted death rates for diabetic hyperglycemic crises",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1794|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/22/36205\" title=\"table 1\">",
"      Precipitating factors DKA and HHS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/19/24892\" title=\"table 2\">",
"      ADA criteria DKA HHS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25511?source=related_link\">",
"      Insulin action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41702?source=related_link\">",
"      Insulin secretion and pancreatic beta-cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/6/25699?source=related_link\">",
"      Patient information: Hyperosmolar nonketotic coma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32920?source=related_link\">",
"      Syndromes of ketosis-prone diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_16_44296="Minimally invasive coronary artery bypass graft surgery: Definitions and technical issues";
var content_f43_16_44296=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Minimally invasive coronary artery bypass graft surgery: Definitions and technical issues",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/16/44296/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44296/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/16/44296/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44296/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44296/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/16/44296/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44296/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/16/44296/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less invasive surgical techniques using laparoscopy and robotics through smaller \"key hole\" incisions with specialized instruments have been applied to many abdominal, urologic, and gynecologic procedures. These alternative approaches are safe and effective, resulting in a reduction in patient discomfort and hospital length of stay and cost.",
"   </p>",
"   <p>",
"    There is increasing experience with the use of similar techniques to open cardiac surgery. The definitions and technical issues related to minimally invasive coronary artery bypass graft surgery (CABG) will be reviewed here. The clinical outcomes with these procedures and minimally invasive approaches to valvular surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37031?source=see_link\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/38/30310?source=see_link\">",
"     \"Minimally invasive aortic and mitral valve surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To appreciate the potential value of minimally invasive CABG, it is useful to first review the complications associated with standard CABG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STANDARD CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery bypass grafting (CABG), especially with the use of the left internal thoracic (mammary) artery to the left anterior descending artery (LAD), relieves symptoms, improves survival, and decreases recurrence of adverse cardiovascular events in selected groups of patients. Durability and survival are further enhanced by the use of more complete arterial revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/1\">",
"     1",
"    </a>",
"    ]. The alternative in patients who need revascularization is percutaneous coronary intervention (PCI), which is now usually performed with implantation of drug-eluting stents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=see_link\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main disadvantage of CABG compared to PCI is the need for surgery and its attendant longer initial recovery period (typically four to six weeks). The main advantages are a lower rate of revascularization (a benefit that is much less prominent with drug-eluting stents), correction of lesions that cannot be adequately treated with PCI (such as total occlusions and very long diffusely diseased lesions) and, in selected patients (particularly diabetics and patients with high Syntax scores), a reduction in long-term mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=see_link\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several principles of surgical revascularization form a baseline against which any new technique, such as minimally invasive surgery, must be compared:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advances in cardiopulmonary bypass techniques and myocardial protection, particularly in cardioplegia delivery and composition, have resulted in superior clinical results by allowing the surgeon to work in a still, quiet field with maximal visualization, permitting precise complex repair and reconstruction while protecting the myocardium.",
"     </li>",
"     <li>",
"      The use of arterial grafting (the internal mammary or thoracic artery) to the left anterior descending (LAD) artery has reduced the incidence of graft occlusion, improved long-term survival, and decreased cardiovascular events (",
"      <a class=\"graphic graphic_figure graphicRef55263 \" href=\"mobipreview.htm?33/36/34381\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef79510 \" href=\"mobipreview.htm?23/40/24205\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/2\">",
"       2",
"      </a>",
"      ]. Furthermore, more complete arterial revascularization with multiple arterial grafts using a second internal mammary artery, a radial artery, and sequential arterial grafting has also decreased cardiac events and improved survival compared to a single arterial graft; the use of multiple grafting is becoming the standard of care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=see_link&amp;anchor=H12#H12\">",
"       \"Long-term outcome after coronary artery bypass graft surgery\", section on 'LIMA plus another arterial graft'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      More complete revascularization, rather than a \"culprit lesion\" approach, has resulted in prolonged survival and reduces the need for reintervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perioperative complications of CABG are discussed in detail separately. Summarized briefly, the perioperative and in-hospital mortality rate average about 1 percent for the lowest risk elective patients, and 2 to 5 percent for all patients, and has been decreasing in the past decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the risk is highly dependent upon comorbid disease, postoperative complications, and the hospital volume of CABG procedures. Other important perioperative complications include myocardial infarction in 2 to 5 percent, stroke and other adverse cerebral outcomes in approximately 2 to 5 percent, renal failure, and wound infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3834?source=see_link\">",
"     \"Neurologic complications of cardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=see_link\">",
"     \"Postoperative mediastinitis after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications related to traditional techniques of cardiac surgery primarily result from cardiopulmonary bypass (CPB). An important factor is aortic instrumentation and manipulation, including cannulation, decannulation, and partial or complete clamping and unclamping, which can result in dislodgement of atherosclerotic debris and embolization from diseased aortas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors that contribute to complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Global cardiac arrest",
"     </li>",
"     <li>",
"      Hypothermia (rarely performed except in complex",
"      <span class=\"nowrap\">",
"       arch/aortic",
"      </span>",
"      procedures)",
"     </li>",
"     <li>",
"      Nonpulsatile bypass and artificial perfusion",
"     </li>",
"     <li>",
"      An intense \"inflammatory\" response mediated by multiple cytokines and chemokines in which circulating leukocytes overexpress adhesion and signaling factors after contact with the artificial (nonendothelialized) surfaces of CPB; with off-pump CABG, some cytokines activated by CPB are not activated and other cytokines are activated to a similar extent but show a delayed response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The reintroduction of fat and particulate debris as well as procoagulant and proinflammatory factors from the pericardial surgical field into the systemic circulation via the use of cardiotomy (field) suction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The sternotomy and skin incision",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the median sternotomy incision permits excellent visualization of all mediastinal structures, it is associated with a rate of infection (including osteomyelitis and mediastinitis) of approximately 1 to 1.5 percent. In addition, this approach requires a period of four to six weeks for bony union, limiting the patient's ability to resume full physical activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H18#H18\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Sternal wound infection and mediastinitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Newer micro-fixation systems utilizing plates and self-locking, self-drilling screws may minimize these complications, especially in higher-risk patients (such as those with obesity, diabetes, osteoporosis, smoking, and COPD).",
"   </p>",
"   <p>",
"    A variety of advances in surgical technique have been made with CABG surgery in an attempt to minimize these complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H5#H5\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Improvements in surgical technique'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MINIMALLY INVASIVE CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many alternatives to traditional cardiac surgical methods are being explored in an attempt to limit morbidity and to eliminate CPB by performing surgery on the beating heart. These varied approaches are all referred to as \"minimally invasive\" techniques. They use less invasive cardiac surgical techniques, such as smaller incisions (limited access) and totally endoscopic \"robotic\" surgery using a computer-enhanced telemanipulation system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Saphenous vein harvest can also be accomplished through small incisions using video-based surgical techniques, decreasing the morbidity associated with leg incision (pain, infection) and permitting more rapid recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term minimally invasive direct CABG or MID CABG (also called minimal or limited access CABG) is applied to procedures that use alternatives to standard median sternotomy, and off-pump CABG or OP CABG when a median sternotomy is utilized. Two alternative techniques have emerged for MID CABG, which differ in the use of CPB.",
"   </p>",
"   <p>",
"    The following discussion will review each of the procedures, with emphasis on advantages and disadvantages, and then the available data on clinical outcomes. The clinical outcomes with these techniques are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BEATING HEART CABG SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beating heart surgery has been advocated to avoid the complications of CPB and artificial perfusion during CABG. As an example, there may be significant reductions in markers of a systemic inflammatory response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] and in intraoperative troponin T release, suggesting less myocyte injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beating heart operations are performed with specialized platforms that enable myocardial surface stabilization and limit myocardial motion and by selective use of temporary endovascular shunts to limit ischemia. Using these technologies, standard and complete surgical anastomoses can be safely and effectively performed. This is known as off-pump or OP CABG.",
"   </p>",
"   <p>",
"    Less invasive minimal access CABG techniques (MID CABG) have emphasized the use of a limited thoracotomy incision as an alternative to median sternotomy, with either direct thoracoscopic or robotic assisted left and right internal mammary artery (IMA) harvesting and direct LIMA to coronary artery anastomotic techniques employing myocardial stabilization (",
"    <a class=\"graphic graphic_figure graphicRef59964 \" href=\"mobipreview.htm?14/23/14707\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82230 \" href=\"mobipreview.htm?21/49/22291\">",
"     figure 4",
"    </a>",
"    ). Myocardial stabilization platforms improve the accuracy and ease of distal anastomosis on the beating heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery on the beating heart poses four technical problems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The motion of the coronary artery hampers accurate anastomotic suturing and in particular complex revascularization (such as endarterectomy).",
"     </li>",
"     <li>",
"      Collateral flow from side branches may obscure the surgical view.",
"     </li>",
"     <li>",
"      Temporary snaring of the coronary artery, in order to enhance visualization, may result in ischemic changes, particularly in patients with active symptoms, limited collateral flow, or depressed ventricular function. Intracoronary shunts may be utilized to minimized interruption of coronary flow during construction of anastomoses. Snaring and intracoronary shunts may result. In an injury to the coronary vessel wall that may lead to a delayed hyperplastic response with a resultant atherosclerotic occlusive lesion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The heart has to be lifted to reach posterior and lateral targets, specifically the circumflex and posterior descending arteries. The resulting anatomical distortion may lead to significant left and right ventricular hemodynamic deterioration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/21\">",
"       21",
"      </a>",
"      ]. These limitations have been addressed by devices that facilitate cardiac displacement (allowing lateral and inferior cardiac exposure) with minimal impediment to caval blood return.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     MID CABG without CPB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique of MID CABG, performed through a limited anterior thoracotomy, is best suited to approach anterior coronary vessels, most commonly the left anterior descending artery (LAD) (",
"    <a class=\"graphic graphic_figure graphicRef62608 \" href=\"mobipreview.htm?8/5/8276\">",
"     figure 5",
"    </a>",
"    ). It can approach vessels that cannot be treated with PCI such as those that have excessive length, angulation, or tortuosity, or complex lesions. Concomitant procedures may be necessary to achieve complete revascularization when multivessel disease is present.",
"   </p>",
"   <p>",
"    One suggested approach is a hybrid procedure consisting of MID CABG with a LIMA (robotic or minimally invasive harvest) to the LAD performed in conjunction with PCI using drug-eluting stents of the right coronary or left circumflex artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This hybrid procedure may be as effective as classic double vessel CABG, but is associated with less perioperative morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With MID CABG, the LIMA is harvested under direct visualization through a small left anterior thoracotomy incision or using endoscopic or robotic techniques through a small port hole incision. Alternative approaches use a free segment of the right internal thoracic artery, radial artery, or saphenous vein, or inferior epigastric artery, one end of which is attached the LIMA (which is anastomosed to the LAD) and the other end to other accessible coronary arteries (diagonal or circumflex branches), forming an \"T\" or \"Y\" graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/25\">",
"     25",
"    </a>",
"    ]. This is meant to avoid aortic manipulation and partial clamping and reduce the risk of peri-operative stroke.",
"   </p>",
"   <p>",
"    The pericardium is opened and cardiac motion is limited using a surface stabilizing platform that facilitates creation of accurate technical anastomoses and is designed to minimize disruption of the adjacent beating heart, thereby preserving global cardiac function (",
"    <a class=\"graphic graphic_figure graphicRef61390 \" href=\"mobipreview.htm?22/24/22918\">",
"     figure 6",
"    </a>",
"    ). Cardiac motion can further be limited by pharmacologic interventions that temporarily decrease the heart rate or cause transient cardiac asystole lasting several seconds. These include adenosine boluses, short acting beta blocker therapy, or vagal stimulation. The more current generation of surface stabilizers have limited the need of adjunctive pharmacological manipulations.",
"   </p>",
"   <p>",
"    Blood flow to the segment of the coronary artery chosen for anastomosis is temporarily interrupted, using specialized vessel loops that occlude the vessel. Alternatively, intracoronary shunts are placed through the opening in the coronary vessel (arteriotomy) to reestablish distal flow and prevent distal ischemia and to improve visualization while the vascular anastomosis is surgically fashioned. A direct anastomosis of the end of the arterial conduit to the side of LAD is performed using conventional techniques.",
"   </p>",
"   <p>",
"    Other coronary arteries can be bypassed via different incision sites:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mid and distal right coronary artery can be approached through appropriately placed right anterior thoracotomy incisions, performing a distal anastomosis using the right internal mammary artery (RIMA).",
"     </li>",
"     <li>",
"      The circumflex artery and its branches can be approached through a left thoracotomy utilizing either the LIMA or the radial artery as a conduit, creating an end-to-side anastomosis (T-graft) from the LIMA to the distal coronary artery beyond the blockage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/3\">",
"       3",
"      </a>",
"      ]. Alternatively, the bypass conduit can be anastomosed directly to the descending thoracic aorta to create inflow.",
"     </li>",
"     <li>",
"      The gastroepiploic artery can be used to bypass the right coronary artery or posterior descending artery through a limited midline laparotomy incision [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Possible advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;With MID CABG, the small thoracic incisions eliminate morbidity related to median sternotomy, resulting in the potential for a more rapid and complete recuperation. However, wound complications still occur in up to 9 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MID CABG without CPB has primarily been used in three different groups of patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low-risk group with anterior lesions, primarily of the LAD.",
"     </li>",
"     <li>",
"      High-risk patients with contraindications to conventional bypass, such as the presence of extensive ascending aortic atheromatous or calcific changes precluding safe aortic instrumentation, in whom incomplete or partial revascularization is being considered.",
"     </li>",
"     <li>",
"      MID CABG also may be useful for patients who require reoperation, but in whom a sternotomy or CPB is contraindicated because of bypass grafts at risk, cardiac structure adherent to the sternum, previous sternal wound infection, mediastinal radiation therapy, or calcified or diffusely atherosclerotic aorta [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Possible disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The small individual incisions with MID CABG permit only limited access to specific regions of the heart, such as the anterior, lateral, and inferior walls. In addition, LIMA and RIMA harvest is technically somewhat more demanding and the distal right coronary artery and the posterior descending artery, which are frequently diseased, are not easily accessed through an anterior thoracotomy incision.",
"   </p>",
"   <p>",
"    Identifying and bypassing small (less than 1.5 mm) intramyocardial or diffusely diseased calcified vessels including those with pre-existing stents may require complex dissection and extensive endarterectomies. These procedures are best avoided with MID CABG. Patient with diffuse CAD can be identified prior to intervention by coronary angiographic data and by high resolution 64 slice CTA assessing endoluminal diameter and characteristics. In addition, temporary snaring of the target vessel may be poorly tolerated particularly in patients with active ischemia, poor collaterals and depressed ventricular function. Those patients will require intra-coronary shunts to minimize distal ischemia.",
"   </p>",
"   <p>",
"    Proximal anastomosis to the ascending aorta is more challenging through these limited incisions. Constructing inflow to secondary graft requires a T or Y anastomosis to the IMA. However, newer stapling devices have been introduced, which facilitate creation of proximal anastomoses and may address this issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     OP CABG via a median sternotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The off-pump CABG, performed without CPB, uses the standard median sternotomy incision, which permits excellent access and visualization to all distal coronary vessels with the use of specialized cardiac retraction and stabilizing systems and techniques.",
"   </p>",
"   <p>",
"    Since surgery is being performed under conditions of a beating, normothermic heart, regional ischemia, particularly when collateral flow is inadequate, is possible during the 5 to 15 minutes required for construction of each anastomosis. Although this does not seem to be a frequent problem, tolerance to ischemia can be enhanced by one of the following procedures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unloading the ventricle either mechanically or pharmacologically",
"     </li>",
"     <li>",
"      Direct intravascular coronary cannulation with an intravascular shunt with passive or active arterial blood perfusion of the distal myocardial bed",
"     </li>",
"     <li>",
"      Ischemic preconditioning using intermittent repeated coronary artery occlusion prior to the definitive surgical arteriotomy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9673?source=see_link\">",
"       \"Definition and pathogenesis of ischemic preconditioning\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Possible advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main advantage of OP CABG is avoiding complications of artificial perfusion and CPB, including reductions in the inflammatory response, postoperative infection, and atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link&amp;anchor=H6#H6\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proximal anastomoses can be performed with partial ascending aortic cross clamping and harvesting of both internal thoracic arteries are readily accomplished using standard techniques and equipment. Multivessel revascularization is more easily accomplished through the median sternotomy incision, which permits access to all coronary vessels and internal thoracic conduits, compared to a more limited anterior thoracotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Possible disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Larger randomized studies suggested a lower extent of revascularization and lower patency rates at one year with OP CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/34\">",
"     34",
"    </a>",
"    ]. Thromboembolic complications are still present with OP CABG, occurring in 1 percent in one review, an incidence comparable to standard CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/35\">",
"     35",
"    </a>",
"    ]. The risk is primarily related to instrumentation and manipulation of an atherosclerotic ascending aorta, especially with partial aortic clamping used to construct proximal anastomoses. In addition, aortic manipulation (without CPB) and partial clamping in a diseased aorta has been associated rarely with aortic dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Although rare, the frequency may be greater than seen with conventional CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H31#H31\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Aortic dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatives approaches, which include newer instrumentation, allows construction of proximal anastomoses without aortic partial clamping. These plug like devices are temporarily inserted into the aorta and allow hemostasis during construction of proximal anastomosis. In addition, in patients who do not tolerate hemodynamics perturbation of OP CABG manipulation, minimized closed CPB with biocompatible circuits and no cardiotomy suction (to minimize inflammatory and hemostatic disturbances) can be used and perform beating heart CABG on CPB. This hybrid strategy minimizes risk related to global cardioplegic arrest.",
"   </p>",
"   <p>",
"    Stapling devices that simultaneously resect (core out) a segment of ascending aorta and create an aortic-venous proximal anastomosis, without the need for partial aortic occlusion may address concerns of aortic manipulation injury and distal embolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/38-43\">",
"     38-43",
"    </a>",
"    ]. Long-term cost efficacy data are not currently available. Preliminary data are disappointing, with a higher than expected rate of proximal restenosis and adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the operation is performed through a standard median sternotomy incision, the risk of sternal infection, malunion and the rate of recuperation is similar to that of conventional CABG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H18#H18\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Sternal wound infection and mediastinitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with beating heart MID CABG, snaring or instrumentation of coronary arteries may lead to transient ischemia or vessel wall injury. Rotation or distortion of the beating heart and vena cavae to allow access to the lateral and inferior coronary vessels may result in transient but significant hemodynamic dysfunction of the right and left ventricle, particularly in patients with limited reserve and extreme anatomy. Novel cardiac apical suction devices may facilitate axial rotation of the heart and expose lateral and inferior vessels with less hemodynamic consequences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mid CABG with CPB",
"    </span>",
"    &nbsp;&mdash;&nbsp;With MID CABG through a limited anterior thoracotomy with CPB, antegrade and retrograde cardioplegia is delivered to produce optimal myocardial protection. The surgeons can work on an empty, decompressed heart in a still and bloodless field, leading to enhanced myocardial protection and better access and freedom to manipulate and expose the entire heart, which is necessary for multivessel CABG.",
"   </p>",
"   <p>",
"    CPB is established peripherally via cannulation of the common femoral artery and vein. Using a Heartport system, an endoaortic (endovascular) balloon cross clamp is placed through the femoral arterial cannula into the ascending aorta under fluoroscopic and transesophageal echocardiographic guidance (",
"    <a class=\"graphic graphic_figure graphicRef81959 \" href=\"mobipreview.htm?4/34/4643\">",
"     figure 7",
"    </a>",
"    ). The LIMA is harvested under direct visualization through an appropriate small anterior thoracotomy incision. The pericardium is opened, the vessels identified, and antegrade and retrograde cardioplegic arrest is accomplished. A direct arterial anastomosis is performed using conventional techniques on the flaccid, vented, and cardioplegic heart.",
"   </p>",
"   <p>",
"    Although all the regions of the heart can be approached through a limited anterior thoracotomy when the heart is arrested and decompressed, the ascending aorta is not readily accessible through this limited approach. The additional inflow required to perfuse distal targets in patients undergoing multivessel grafting is provided by anastomosing these conduits to the ascending aorta.",
"   </p>",
"   <p>",
"    To allow adequate visualization and construction of an accurate proximal technical anastomosis, the more limited thoracotomy incision frequently needs to be extended to allow partial aortic cross clamping that is required to create proximal ascending aortic anastomoses, which are performed prior to endoaortic balloon cross clamping. There are two other options: additional conduits can be anastomosed proximally to the LIMA to LAD graft in a T or Y-fashion or to the proximal subclavian artery through a separate incision; or new proximal stapling devices can be used to construct proximal saphenous venous anastomoses on the proximal ascending aorta. These devices have the potential added advantage of minimizing aortic manipulation and potential embolization associated with the partial occlusion aortic clamp technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Possible advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with MID CABG without CPB, this technique can approach multiple vessels that cannot be treated with PCI. Small thoracic incisions eliminate morbidity related to median sternotomy, resulting in more rapid and complete recuperation. Antegrade and retrograde cardioplegia delivery produces maximal myocardial protection. The surgeons can work on an empty, decompressed heart in a still and bloodless field, leading to enhanced technical accuracy and better access when multi-vessel CABG is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Possible disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;LIMA and RIMA harvest is more technically demanding with MID CABG compared with a conventional CABG with median sternotomy approach and requires different instrumentation. In addition, the technique requires both aortic manipulation and conventional CPB. Since these aspects of CABG are most responsible for the inherent risk of the procedure, the thromboembolic and \"inflammatory\" complications are not attenuated.",
"   </p>",
"   <p>",
"    Ascending aortic atherosclerosis precludes safe positioning, manipulation and inflation of the endoaortic cross clamp, while peripheral vascular disease precludes use of femoral cannulation and safe positioning of the endoaortic balloon clamp. As a result, careful patient selection and preoperative evaluation of the aorto-ilio-femoral tree is recommended, adding cost to the procedure.",
"   </p>",
"   <p>",
"    Retrograde perfusion carries a 1 to 2 percent risk of vascular complications, including distal embolization, thrombosis, or arterial dissection. Alternatively, in patients with known peripheral vascular disease, aortic cannulation or subclavian cannulation directly or through a constructed graft allows safer antegrade flow.",
"   </p>",
"   <p>",
"    Because of limited access to the ascending aorta, creating proximal anastomoses is more complex and may lead to morbidity. To avoid this problem, distal grafts can be connected to the LIMA in a T or Y fashion, thereby creating a single and perhaps limited inflow to multiple distal targets. Alternatively, proximal grafting is performed to the subclavian artery through a second incision or ascending aorta using a partial occlusion clamp on CPB, through a second limited incision. Another approach is the use of a specialized stapling device to construct proximal anastomoses; the long-term efficacy of this approach is not yet known.",
"   </p>",
"   <p>",
"    Finally, there are significant additional expenses, complexity, and added operating room costs associated with the use of the Heartport system, which requires specialized instruments, routine fluoroscopy, transesophageal echocardiography (TEE), specialized training, and technical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113901358\">",
"    <span class=\"h2\">",
"     Hybrid procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mid CABG with LIMA to the left anterior descending (LAD) artery has been used more recently as a hybrid with PCI to non-LAD targets or coronary targets that would have been bypassed with saphenous vein bypass (SVG) grafts. Percutaneous coronary intervention with drug-eluting stents can be performed immediately or staged shortly after CABG, with post procedure imaging to ensure patency. This approach highlights the durability and survival advantage of arterial grafting, especially to the LAD with less invasive DES PCI to other coronary targets, avoiding concerns over long-term patency of SVG, particularly in patients with risk for CPB (atherosclerotic aorta, COPD, renal dysfunction) in whom an OP CABG would be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC CABG WITH CPB",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited experience with totally endoscopic CABG with CPB using a robotically enhanced telemanipulation system in patients with single or double vessel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. a one report of 45 such patients who underwent IMA grafting, most achieved excellent patency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44296/abstract/12\">",
"     12",
"    </a>",
"    ]. The need for conversion to an open procedure fell from an initial rate of 22 percent to 5 percent in the last 20 patients; other complications also became less common. However, the mean procedural time for single vessel bypass was 4.2 hours, the mean CPB time was 2.3 hours, and the complex endoscopic and endoaortic occlusion techniques are demanding. Further experience is clearly required to determine the role, if any, for this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H463840706\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitions and technical issues related to minimally invasive coronary artery bypass graft surgery (CABG) are reviewed here. The clinical outcomes with this procedure are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37031?source=see_link\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following represent important points in this topic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many alternatives to traditional cardiac surgical methods have been evaluated in an attempt to limit the morbidity associated with median sternotomy and cardiopulmonary bypass. These varied approaches are all referred to as \"minimally invasive\" techniques. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Standard CABG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The term minimally invasive direct CABG or MID CABG (also called minimal or limited access CABG) is applied to procedures that use alternatives to standard median sternotomy, and off-pump CABG or off-pump (OP) CABG when a median sternotomy is utilized. With MID CABG, the small thoracic incisions eliminate morbidity related to median sternotomy, resulting in the potential for a more rapid and complete recuperation.",
"     </li>",
"     <li>",
"      Two alternative techniques have emerged for MID CABG, which differ in the use of cardiopulmonary bypass (CPB).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With MID CABG through a limited anterior thoracotomy with CPB, antegrade and retrograde cardioplegia is delivered to produce optimal myocardial protection. The surgeons can work on an empty, decompressed heart in a still and bloodless field, leading to enhanced myocardial protection and better access and freedom to manipulate and expose the entire heart, which is necessary for multivessel CABG.",
"     </li>",
"     <li>",
"      MID CAB without CPB is performed through a limited anterior thoracotomy and is best suited to approach anterior coronary vessels, most commonly the left anterior descending artery (LAD). In this procedure the left internal mammary artery is anastomosed to the LAD.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/1\">",
"      Lytle BW, Blackstone EH, Loop FD, et al. Two internal thoracic artery grafts are better than one. J Thorac Cardiovasc Surg 1999; 117:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/2\">",
"      Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986; 314:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/3\">",
"      Tector AJ, Kress DC, Downey FX, Schmahl TM. Complete revascularization with internal thoracic artery grafts. Semin Thorac Cardiovasc Surg 1996; 8:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/4\">",
"      Schmidt SE, Jones JW, Thornby JI, et al. Improved survival with multiple left-sided bilateral internal thoracic artery grafts. Ann Thorac Surg 1997; 64:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/5\">",
"      Aldea GS, Mokadam NA, Melford R Jr, et al. Changing volumes, risk profiles, and outcomes of coronary artery bypass grafting and percutaneous coronary interventions. Ann Thorac Surg 2009; 87:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/6\">",
"      Tomic V, Russwurm S, M&ouml;ller E, et al. Transcriptomic and proteomic patterns of systemic inflammation in on-pump and off-pump coronary artery bypass grafting. Circulation 2005; 112:2912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/7\">",
"      Reents W, Babin-Ebell J, Misoph MR, et al. Influence of different autotransfusion devices on the quality of salvaged blood. Ann Thorac Surg 1999; 68:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/8\">",
"      Aldea GS, Soltow LO, Chandler WL, et al. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 2002; 123:742.",
"     </a>",
"    </li>",
"    <li>",
"     Kirklin JW, Barrat-Boyes BG. Cardiac Surgery. Morphology, diagnostic criteria, natural history, techniques, results and indications, 2nd ed, Churchill Livingstone, New York 1993. p.73.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/10\">",
"      Loop FD, Lytle BW, Cosgrove DM, et al. J. Maxwell Chamberlain memorial paper. Sternal wound complications after isolated coronary artery bypass grafting: early and late mortality, morbidity, and cost of care. Ann Thorac Surg 1990; 49:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/11\">",
"      Mohr FW, Falk V, Diegeler A, et al. Computer-enhanced \"robotic\" cardiac surgery: experience in 148 patients. J Thorac Cardiovasc Surg 2001; 121:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/12\">",
"      Dogan S, Aybek T, Andressen E, et al. Totally endoscopic coronary artery bypass grafting on cardiopulmonary bypass with robotically enhanced telemanipulation: report of forty-five cases. J Thorac Cardiovasc Surg 2002; 123:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/13\">",
"      Vrancic JM, Piccinini F, Vaccarino G, et al. Endoscopic saphenous vein harvesting: initial experience and learning curve. Ann Thorac Surg 2000; 70:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/14\">",
"      Black EA, Guzik TJ, West NE, et al. Minimally invasive saphenous vein harvesting: effects on endothelial and smooth muscle function. Ann Thorac Surg 2001; 71:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/15\">",
"      Gu YJ, Mariani MA, van Oeveren W, et al. Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting. Ann Thorac Surg 1998; 65:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/16\">",
"      Str&uuml;ber M, Cremer JT, Gohrbandt B, et al. Human cytokine responses to coronary artery bypass grafting with and without cardiopulmonary bypass. Ann Thorac Surg 1999; 68:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/17\">",
"      Koh TW, Carr-White GS, DeSouza AC, et al. Intraoperative cardiac troponin T release and lactate metabolism during coronary artery surgery: comparison of beating heart with conventional coronary artery surgery with cardiopulmonary bypass. Heart 1999; 81:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/18\">",
"      Calafiore AM, Giammarco GD, Teodori G, et al. Left anterior descending coronary artery grafting via left anterior small thoracotomy without cardiopulmonary bypass. Ann Thorac Surg 1996; 61:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/19\">",
"      Subramanian VA. Less invasive arterial CABG on a beating heart. Ann Thorac Surg 1997; 63:S68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/20\">",
"      Gundry SR, Romano MA, Shattuck OH, et al. Seven-year follow-up of coronary artery bypasses performed with and without cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998; 115:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/21\">",
"      Geskes GG, Dekker AL, van der Veen FH, et al. The enabler right ventricular circulatory support system for beating heart coronary artery bypass graft surgery. Ann Thorac Surg 1999; 68:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/22\">",
"      Cohen HA, Zenati M, Smith AJ, et al. Feasibility of combined percutaneous transluminal angioplasty and minimally invasive direct coronary artery bypass in patients with multivessel coronary artery disease. Circulation 1998; 98:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/23\">",
"      Isomura T, Suma H, Horii T, et al. Minimally invasive coronary artery revascularization: off-pump bypass grafting and the hybrid procedure. Ann Thorac Surg 2000; 70:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/24\">",
"      de Canni&egrave;re D, Jansens JL, Goldschmidt-Clermont P, et al. Combination of minimally invasive coronary bypass and percutaneous transluminal coronary angioplasty in the treatment of double-vessel coronary disease: Two-year follow-up of a new hybrid procedure compared with \"on-pump\" double bypass grafting. Am Heart J 2001; 142:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/25\">",
"      Cohn WE, Suen HC, Weintraub RM, Johnson RG. The \"H\" graft: an alternative approach for performing minimally invasive direct coronary artery bypass. J Thorac Cardiovasc Surg 1998; 115:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/26\">",
"      Voutilainen S, Verkkala K, J&auml;rvinen A, et al. Minimally invasive coronary artery bypass grafting using the right gastroepiploic artery. Ann Thorac Surg 1998; 65:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/27\">",
"      Grandjean JG, Mariani MA, Ebels T. Coronary reoperation via small laparotomy using right gastroepiploic artery without CPB. Ann Thorac Surg 1996; 61:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/28\">",
"      Ng PC, Chua AN, Swanson MS, et al. Anterior thoracotomy wound complications in minimally invasive direct coronary artery bypass. Ann Thorac Surg 2000; 69:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/29\">",
"      Boonstra PW, Grandjean JG, Mariani MA. Reoperative coronary bypass grafting without cardiopulmonary bypass through a small thoracotomy. Ann Thorac Surg 1997; 63:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/30\">",
"      Azoury FM, Gillinov AM, Lytle BW, et al. Off-pump reoperative coronary artery bypass grafting by thoracotomy: patient selection and operative technique. Ann Thorac Surg 2001; 71:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/31\">",
"      Heijmen RH, Hinchliffe P, Borst C, et al. A novel one-shot anastomotic stapler prototype for coronary bypass grafting on the beating heart: feasibility in the pig. J Thorac Cardiovasc Surg 1999; 117:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/32\">",
"      Ascione R, Lloyd CT, Underwood MJ, et al. Inflammatory response after coronary revascularization with or without cardiopulmonary bypass. Ann Thorac Surg 2000; 69:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/33\">",
"      Ascione R, Caputo M, Calori G, et al. Predictors of atrial fibrillation after conventional and beating heart coronary surgery: A prospective, randomized study. Circulation 2000; 102:1530.",
"     </a>",
"    </li>",
"    <li>",
"     Shoyer, et al. NEJM 2009, 316:1827.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/35\">",
"      Cartier R, Robitaille D. Thrombotic complications in beating heart operations. J Thorac Cardiovasc Surg 2001; 121:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/36\">",
"      Chavanon O, Carrier M, Cartier R, et al. Increased incidence of acute ascending aortic dissection with off-pump aortocoronary bypass surgery? Ann Thorac Surg 2001; 71:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/37\">",
"      De Smet JM, Stefanidis C. Acute aortic dissection after off-pump coronary artery surgery. Eur J Cardiothorac Surg 2003; 24:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/38\">",
"      Caiati JM, Madigan JD, Bhagat G, et al. Vascular clips have no significant effect on the cellular proliferation, intimal changes, or peak systolic velocity at anastomoses in rabbit vein grafts. J Surg Res 2000; 92:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/39\">",
"      Chavanon O, Perrault LP, Menasch&eacute; P. Favorable aspect of stapled anastomosis: an endothelial function study. Ann Thorac Surg 1999; 68:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/40\">",
"      Katariya K, Yassin S, Tehrani HY, et al. Initial experience with sutureless proximal anastomoses performed with a mechanical connector leading to clampless off-pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/41\">",
"      Cavendish JJ, Penny WF, Madani MM, et al. Severe ostial saphenous vein graft disease leading to acute coronary syndromes following proximal aorto-saphenous anastomoses with the symmetry bypass connector device: is it a suture device or a \"stent\"? J Am Coll Cardiol 2004; 43:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/42\">",
"      Traverse JH, Mooney MR, Pedersen WR, et al. Clinical, angiographic, and interventional follow-up of patients with aortic-saphenous vein graft connectors. Circulation 2003; 108:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/43\">",
"      Dewey TM, Crumrine K, Herbert MA, et al. First-year outcomes of beating heart coronary artery bypass grafting using proximal mechanical connectors. Ann Thorac Surg 2004; 77:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/44\">",
"      Jones ML, Qiu S, Sudarshan C. Perioperative outcomes in hybrid versus conventional surgical coronary artery revascularisation. Interact Cardiovasc Thorac Surg 2010; 11:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/45\">",
"      Sabatier B, Trinquart L, Emmerich J. Dual antiplatelet therapy in the secondary prevention of atherothrombosis: need for new therapeutic approaches. Arch Cardiovasc Dis 2010; 103:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44296/abstract/46\">",
"      DeRose JJ. Current state of integrated \"hybrid\" coronary revascularization. Semin Thorac Cardiovasc Surg 2009; 21:229.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1559 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-201.211.0.116-491BB07E26-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44296=[""].join("\n");
var outline_f43_16_44296=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H463840706\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STANDARD CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MINIMALLY INVASIVE CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BEATING HEART CABG SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MID CABG without CPB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Possible advantages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Possible disadvantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OP CABG via a median sternotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Possible advantages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Possible disadvantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mid CABG with CPB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Possible advantages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Possible disadvantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H113901358\">",
"      Hybrid procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ENDOSCOPIC CABG WITH CPB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H463840706\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1559\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1559|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/36/34381\" title=\"figure 1\">",
"      Reoperation rates for arterial versus venous grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/40/24205\" title=\"figure 2\">",
"      Survival with arterial versus venous aortocoronary grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/23/14707\" title=\"figure 3\">",
"      MID CABG incisions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/49/22291\" title=\"figure 4\">",
"      Single vessel grafting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/5/8276\" title=\"figure 5\">",
"      Technique end to side grafting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/24/22918\" title=\"figure 6\">",
"      Coronary stabilizer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/34/4643\" title=\"figure 7\">",
"      Heartport bypass system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9673?source=related_link\">",
"      Definition and pathogenesis of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/38/30310?source=related_link\">",
"      Minimally invasive aortic and mitral valve surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3834?source=related_link\">",
"      Neurologic complications of cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=related_link\">",
"      Postoperative mediastinitis after cardiac surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_16_44297="Treatment of eosinophilic esophagitis";
var content_f43_16_44297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of eosinophilic esophagitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/16/44297/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44297/contributors\">",
"     Peter A L Bonis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44297/contributors\">",
"     Glenn T Furuta, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/16/44297/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44297/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/16/44297/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/16/44297/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/16/44297/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal eosinophilia has been described in association with eosinophilic gastroenteritis, an uncommon condition that can cause a range of symptoms, including malabsorption, dysmotility, and ascites, depending upon the layer of the intestinal tract that is involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. When the gastrointestinal eosinophilia is limited to the esophagus and is accompanied by characteristic symptoms, it is termed eosinophilic esophagitis. Eosinophilic esophagitis is an increasingly recognized cause of dysphagia and possibly heartburn that is unresponsive to antireflux measures.",
"   </p>",
"   <p>",
"    The management of eosinophilic esophagitis includes dietary, pharmacologic, and endoscopic interventions. The approach to patients with eosinophilic esophagitis is based primarily on clinical experience, case series, and small controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In addition, it is uncertain whether treatment of symptoms alone is sufficient or if resolution of the eosinophilic inflammation is required.",
"   </p>",
"   <p>",
"    Commonly used treatments include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elimination and elemental diets to decrease allergen exposure",
"     </li>",
"     <li>",
"      Acid suppression to treat gastroesophageal reflux disease, which may mimic or contribute to eosinophilic esophagitis",
"     </li>",
"     <li>",
"      Topical glucocorticoids to decrease esophageal inflammation",
"     </li>",
"     <li>",
"      Esophageal dilation to treat strictures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other treatments that have been studied include systemic glucocorticoids, antihistamines, immunosuppressants, and immunomodulators.",
"   </p>",
"   <p>",
"    This topic will review the treatment of eosinophilic esophagitis. The approaches outlined are consistent with a 2011 consensus statement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/6\">",
"     6",
"    </a>",
"    ]. The pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis in adults and children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60192545\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data regarding the natural history of eosinophilic esophagitis. However, the available data suggest dysphagia persists in patients who do not receive treatment. In one study of 30 untreated patients followed for an average of 7.2 years, dysphagia persisted in 29 (97 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/7\">",
"     7",
"    </a>",
"    ]. During follow-up, symptoms increased in 23 percent, were stable in 37 percent, and decreased in 37 percent. Attacks of dysphagia occurred more frequently in patients with blood eosinophilia or with pronounced findings on endoscopy. All patients maintained adequate caloric intake and body weight. Eleven patients were treated with esophageal dilation (seven had a single dilation and four had repeat dilations), which was at least partially successful in 10 (at least a 50 percent reduction in dysphagia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2895691\">",
"    <span class=\"h1\">",
"     DIETARY THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary therapy is an effective treatment for eosinophilic esophagitis in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Dietary therapy is based upon the observation that patients with eosinophilic esophagitis have high rates of food allergies, and that those allergies may contribute to the development of eosinophilic esophagitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link&amp;anchor=H1536312#H1536312\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\", section on 'Environmental factors and T-cell immunity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The appeal of the dietary approach is that it potentially offers an effective non-pharmacologic treatment. On the other hand, allergen avoidance with elimination and elemental diets poses a risk of nutritional deprivation, can be difficult for patients and families (particularly if nasogastric feedings are required), can lead to psychological problems, and may lead to unnecessary food aversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In addition, relapse upon discontinuation of the diet is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/9\">",
"     9",
"    </a>",
"    ]. When used, elemental and elimination diets should be administered under the supervision of a registered dietician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We refer both adults and children to an allergist with expertise in the evaluation of food allergies. We suggest avoidance of known allergens (both food and environmental) for patients in whom specific allergies can be identified after discussion of the pros and cons of the dietary approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2895768\">",
"    <span class=\"h2\">",
"     Elimination diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three general approaches can be taken when implementing an elimination diet. The first is to perform testing for food allergies, with subsequent elimination of foods with positive test results. The second is to empirically eliminate foods to which patients are most likely to be allergic. Common food allergies in adults with eosinophilic esophagitis include peanuts, eggs, soy, cow&rsquo;s milk, wheat, and tree nuts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The third involves the use of an elemental formula that eliminates all potential food proteins (see",
"    <a class=\"local\" href=\"#H2895775\">",
"     'Elemental diets'",
"    </a>",
"    below). Once symptoms are controlled, foods may be able to be sequentially reintroduced. Any foods that result in worsening of symptoms should be avoided indefinitely. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83815940\">",
"    <span class=\"h3\">",
"     Elimination diets in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large series that looked at the use of elimination diets included 146 children who were treated with an elimination diet guided by the results of skin prick and patch testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. Resolution of esophageal eosinophilia was observed in 77 percent (including 39 patients in whom esophageal eosinophilia returned upon reintroduction of the offending food) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/15\">",
"     15",
"    </a>",
"    ]. Egg, milk, and soy were identified most frequently with skin prick testing, while corn, soy, and wheat were identified most frequently with atopy patch testing. On average, four causative foods were identified per patient, although one patient had 11.",
"   </p>",
"   <p>",
"    While this approach appears promising, food allergy testing (particularly patch testing) has not yet been standardized and additional follow-up is required to understand the long-term benefits. Furthermore, the above study was retrospective, uncontrolled, and not systematic, thus leaving considerable uncertainty regarding the predictive ability of the allergy testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observational study compared outcomes in 98 children with eosinophilic esophagitis who had been treated with either an elemental diet (see",
"    <a class=\"local\" href=\"#H2895775\">",
"     'Elemental diets'",
"    </a>",
"    below), a diet in which six foods associated with allergy were eliminated (ie, cow-milk protein, soy, wheat, egg, peanut, and seafood), or a skin prick allergy testing-directed elimination diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/19\">",
"     19",
"    </a>",
"    ]. Histologic remission occurred in children on all three diets (96, 81, and 65 percent, respectively). However, the odds of histologic remission were significantly higher in children on elemental diets compared with directed diets (OR 12.5, 95% CI 2.3-65.6). There was no significant difference in histologic remission rates between children on an elemental diet and a six-food elimination diet (OR 5.6, 95% CI 1.0-31.2). In another observational study in which 60 children were treated with either an elemental diet, or a six-food elimination diet, the authors found a similar degree of clinical and histologic improvement but improved acceptance, lower costs, and better compliance with the six-food elimination diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83815947\">",
"    <span class=\"h3\">",
"     Elimination diets in adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The six-food elimination diet has also been studied in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In a study of 50 adults with eosinophilic esophagitis, patients were treated with the six-food elimination diet for six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/21\">",
"     21",
"    </a>",
"    ]. This diet was based on excluding the six most common food allergens and was not based on specific food allergy testing. At the end of six weeks, a clinical response (decreased dysphagia) was seen in 94 percent of patients, the endoscopic appearance improved in 78 percent, and esophageal biopsies revealed at least a 50 percent reduction in eosinophils in 78 percent. A clinical response was more common in patients who initially had heartburn or who started the six-food elimination diet during the final three years of the study (possibly reflecting increasing experience in coaching patients to adhere to the diet). However, while 94 percent of patients showed clinical improvement, only 74 percent had a reduction in their eosinophil count to less than 15",
"    <span class=\"nowrap\">",
"     eosinophils/hpf.",
"    </span>",
"   </p>",
"   <p>",
"    After six weeks, patients gradually reintroduced food groups and follow-up data were available in 20 patients. In all 20 patients, a specific food could be implicated in inciting the esophageal eosinophilia. The most common food triggers were wheat (60 percent) and milk (50 percent). Seafood was not a trigger for any patient. Skin-prick allergy testing identified only 13 percent of the food triggers.",
"   </p>",
"   <p>",
"    These studies suggest that six-food elimination diets for six weeks followed by individually tailored exclusion diets may be an option for motivated adults. However, successful implementation of such diets requires a dedicated and informed nutritionist and willingness on the part of the patient to make substantial lifestyle changes. In addition, patients will need to undergo multiple endoscopies to determine which food group is the trigger.",
"   </p>",
"   <p>",
"    These observations also question the value of traditional allergy testing in identifying the implicated foods. Nevertheless, referring patients to an allergist may lead to an improvement in quality of life through treatment of patients with an overall allergic diathesis.",
"   </p>",
"   <p>",
"    While it is unclear if adults will adhere to an elimination diet long-term, among the few patients who have been studied, clinical and histologic improvement (although not always normalization) appears to be sustained for up to three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2895775\">",
"    <span class=\"h2\">",
"     Elemental diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consumption of an elemental diet provides another means to limit the intake of potential food allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. An elemental diet is composed of an elemental formula in which the protein source is comprised of synthetic amino acids. Elemental diets are unpalatable and expensive. They have been studied almost exclusively in children and data in adults are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest series included 51 children and adolescents who were treated with an elemental diet that consisted of free amino acids, corn syrup solids, and medium-chain triglyceride oil (Neocate-1-Plus, SHS North America, Gaithersburg, MD) delivered orally (to three patients) or via a nasogastric tube (to 48 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients were allowed to consume water and one fruit (either grape or apple) and its corresponding pure juice. They were also maintained on a proton pump inhibitor.",
"   </p>",
"   <p>",
"    Significant improvement in vomiting, abdominal pain, and dysphagia were observed an average of 8.5 days after beginning treatment in all but two patients. A repeat endoscopy with biopsies was performed one month after beginning treatment and revealed a corresponding significant decrease in esophageal eosinophils. The long-term efficacy of treatment was not described, although the authors suggested that they reintroduced single foods every five to seven days while simultaneously observing clinical symptoms and repeating an endoscopy with biopsy in ambiguous cases.",
"   </p>",
"   <p>",
"    Symptomatic and histologic improvement was also observed in an earlier report using a similar approach in 10 children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the median time to symptom relief was three weeks (range two to six weeks).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H209980\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acid suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between gastroesophageal reflux disease (GERD) and eosinophilic esophagitis is unclear. GERD may be a mimic of eosinophilic esophagitis, coexist with it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/26\">",
"     26",
"    </a>",
"    ], or contribute to it. Conversely, eosinophilic esophagitis may contribute to GERD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/27\">",
"     27",
"    </a>",
"    ]. The diagnosis of eosinophilic esophagitis should generally include demonstration of persistent esophageal eosinophilia after treatment with a proton pump inhibitor (or with a normal pH study). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\", section on 'Distinction from GERD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proton pump inhibitors may benefit patients with esophageal eosinophilia either by reducing acid production in patients with co-existent GERD, or by other yet undefined anti-inflammatory mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/28\">",
"     28",
"    </a>",
"    ]. Acid-suppressing therapy may also be helpful in patients with established eosinophilic esophagitis, since the already inflamed esophagus may be predisposed to injury and more sensitive to physiologic acid exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasional patients have a good clinical and histologic response to proton pump inhibitors alone, suggesting that GERD, or a PPI-responsive form of esophageal eosinophilia, may be responsible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In a randomized trial, 42 patients with newly diagnosed eosinophilic esophagitis were randomly assigned to treatment with aerosolized swallowed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    (440 mcg twice daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    (40 mg daily) for eight weeks followed by an upper endoscopy with biopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/32\">",
"     32",
"    </a>",
"    ]. In patients without coexisting GERD, there was no significant difference in resolution of esophageal eosinophilia between the esomeprazole and fluticasone treatment arms (18 versus 24 percent). In contrast, among patients with GERD, those treated with esomeprazole were significantly more likely to have resolution of esophageal eosinophilia as compared with fluticasone (100 versus 0 percent). However, regardless of the presence of GERD, treatment with esomeprazole, but not fluticasone, was associated with a significant improvement in symptoms of dysphagia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Topical glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with eosinophilic esophagitis respond to topical glucocorticoids as demonstrated by a decrease in eosinophil counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/26,33,34\">",
"     26,33,34",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     Fluticasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/45/33488?source=see_link\">",
"     ciclesonide",
"    </a>",
"    have been studied. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .) No formulation of topical glucocorticoids has been approved specifically for eosinophilic esophagitis. We treat most adult patients with swallowed fluticasone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/26,33,35-40\">",
"     26,33,35-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized controlled trials have not consistently demonstrated an improvement in dysphagia with topical glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/34,41\">",
"     34,41",
"    </a>",
"    ]. It is unclear if this is due to differences in patient selection, definitions of symptom response, steroid formulations and duration of treatment, or dietary modification that may have resulted in a higher placebo response rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/42\">",
"     42",
"    </a>",
"    ]. Long-term steroid use is associated with side effects and symptoms often recur when steroids are discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fluticasone propionate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     Fluticasone",
"    </a>",
"    is administered using a metered dose inhaler without a spacer. The medication is sprayed into the patient&rsquo;s mouth and then swallowed. Patients should",
"    <strong>",
"     not",
"    </strong>",
"    inhale when the medication is being delivered and they should not eat or drink for 30 minutes following administration.",
"   </p>",
"   <p>",
"    The optimal dose has not been established. Our approach is based upon the patient's age:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children from 1 to 4 years of age: 44 mcg inhaler, two sprays twice daily",
"     </li>",
"     <li>",
"      Children from 5 to 10 years of age: 110 mcg inhaler, two sprays twice daily",
"     </li>",
"     <li>",
"      Patients &ge;11 years of age (including adults): 220 mcg inhaler, two sprays twice daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment is generally well-tolerated and patients who are destined to respond tend to do so quickly (within one week and often within one to two days). Patients frequently relapse when treatment is stopped, with reported relapse rates of 14 to 91 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/26,43-45\">",
"     26,43-45",
"    </a>",
"    ]. For patients who relapse, we repeat treatment for four to six weeks.",
"   </p>",
"   <p>",
"    Maintenance therapy has not yet been standardized. Because eosinophilic esophagitis is a chronic disease, we suggest ongoing treatment, whether medical or nutritional. Some authorities treat on an as-needed basis, while others will use the lowest dose possible of topical glucocorticoids that allow patients to remain asymptomatic. Our approach is to continue nutritional therapy, using topical glucocorticoids as needed in doses and intervals that keep patients asymptomatic (see",
"    <a class=\"local\" href=\"#H2895691\">",
"     'Dietary therapy'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Representative studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    for eosinophilic esophagitis have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series in adults included 21 patients who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      propionate 220 mcg twice daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/44\">",
"       44",
"      </a>",
"      ]. All patients had relief of dysphagia that lasted a minimum of four months. Relief often occurred within a few days after beginning treatment. Three patients (14 percent) relapsed and required additional therapy. Histologic outcomes were not assessed. However, in a later series, clinical improvement was associated with a significant decrease in esophageal eosinophil counts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/26\">",
"       26",
"      </a>",
"      ]. The only adverse effect noted was dry mouth.",
"     </li>",
"     <li>",
"      Similar benefits have been observed in children, although different doses and dosing intervals have been used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/33,36,40,45\">",
"       33,36,40,45",
"      </a>",
"      ]. The largest controlled trial included 36 children who were randomly assigned to swallowed",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      (880",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      in two divided doses) or placebo for three months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/33\">",
"       33",
"      </a>",
"      ]. Histologic remission was observed significantly more often in the fluticasone group (50 versus 9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Side effects that have been reported with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    for eosinophilic esophagitis include candidal esophagitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/36,45\">",
"     36,45",
"    </a>",
"    ] and herpes esophagitis was noted in a case report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, in diseases other than eosinophilic esophagitis, inhaled doses of fluticasone higher than 440",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    have been associated with systemic side effects including cataracts, impaired growth in children, and adrenal suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. It is not known if the risk of these side effects is reduced when fluticasone is swallowed and undergoes first-pass metabolism in the liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Budesonide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     Budesonide",
"    </a>",
"    has been evaluated in case series and randomized trials and appears to be effective for treating eosinophilic esophagitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/41,49-55\">",
"     41,49-55",
"    </a>",
"    ]. Budesonide can be administered using a nebulizer and patients are then instructed to swallow the accumulated liquid or as an oral viscous slurry (1 mg daily for children under the age of 10 years, and 2 mg daily for older children and adults). Viscous budesonide can be compounded by mixing two or four 0.5",
"    <span class=\"nowrap\">",
"     mg/2mL",
"    </span>",
"    Pulmicort Respules&trade; with sucralose (Splenda&trade;; ten 1-gram packets per 1 mg of budesonide, creating a volume of approximately 8 mL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients should not eat or drink for 30 minutes after taking the budesonide suspension.",
"   </p>",
"   <p>",
"    In a randomized trial, 22 patients with eosinophilic esophagitis were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    either nebulized and then swallowed or as an oral viscous slurry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/56\">",
"     56",
"    </a>",
"    ]. Although patients who received the viscous slurry had a higher duration of mucosal contact with budesonide and lower eosinophil count, there was no significant difference in dysphagia symptom scores which improved in both groups.",
"   </p>",
"   <p>",
"    Studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    for eosinophilic esophagitis have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial with 24 children, the response rate, defined as an eosinophilic count",
"      <span class=\"nowrap\">",
"       &le;6/hpf",
"      </span>",
"      was significantly higher with oral viscous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (87 versus 0 percent with placebo) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/41\">",
"       41",
"      </a>",
"      ]. Symptoms, endoscopic findings, and histologic features improved after treatment. Patients in both groups were also treated with a proton pump inhibitor. Since there were no responders in the placebo group, monotherapy with a proton pump inhibitor had no benefit.",
"     </li>",
"     <li>",
"      Similar benefits have been described in studies in adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/51,52,55\">",
"       51,52,55",
"      </a>",
"      ]. In a randomized trial, 36 adults and adolescents with active eosinophilic esophagitis were randomized to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      1 mg twice daily or placebo for 15 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/55\">",
"       55",
"      </a>",
"      ]. The budesonide was administered using a nebulizer and patients were instructed to continuously swallow the accumulated liquid. Patients who received budesonide were more likely to have significant improvements in dysphagia compared with those who received placebo (72 versus 22 percent). In addition, patients treated with budesonide showed histologic improvement, whereas those treated with placebo did not.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450744934\">",
"    <span class=\"h3\">",
"     Ciclesonide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/45/33488?source=see_link\">",
"     Ciclesonide",
"    </a>",
"    , a topical glucocorticoid with less systemic absorption than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    , has been evaluated in small case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. In one report, four children who had either failed therapy with fluticasone or dietary restriction, or whose parents were concerned about steroid exposure, were treated with swallowed topical ciclesonide (80 or 160 mcg, two sprays twice daily) for two months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/58\">",
"     58",
"    </a>",
"    ]. Symptoms resolved in all four patients and there was a significant decrease in eosinophil counts in both proximal and distal esophageal biopsy specimens at two months (proximal: 71&plusmn; 25.5 versus 1.8 &plusmn; 2",
"    <span class=\"nowrap\">",
"     eosinophils/hpf",
"    </span>",
"    before and after treatment; distal: 76.3&plusmn; 33 versus 0.75 &plusmn; 1.5",
"    <span class=\"nowrap\">",
"     eosinophils/hpf",
"    </span>",
"    before and after treatment). Further studies are needed before ciclesonide can be recommended for patients with eosinophilic esophagitis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210774\">",
"    <span class=\"h3\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high relapse rate following discontinuation of treatment with topical glucocorticoids has led to investigations of maintenance therapy with topical steroids for patients with eosinophilic esophagitis. Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    was used in a randomized trial in 28 adults with eosinophilic esophagitis who were in clinical remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/54\">",
"     54",
"    </a>",
"    ]. The patients were assigned to twice daily budesonide (0.25 mg) or placebo for a total of 50 weeks. The eosinophil load increased over the course of treatment in both groups, but the increase was less in those treated with budesonide (from 0.4 to 32",
"    <span class=\"nowrap\">",
"     eosinophils/hpf)",
"    </span>",
"    than in those treated with placebo (from 0.7 to 65",
"    <span class=\"nowrap\">",
"     eosinophils/hpf).",
"    </span>",
"   </p>",
"   <p>",
"    Over",
"    the course of the study, patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    did not report a statistically significant increase in symptoms, whereas those who received placebo did. At the end of the study, patients who received budesonide were more likely to be in clinical remission (64 versus 36 percent). Patients treated with budesonide also showed evidence of esophageal remodelling. At baseline, patients with eosinophilic esophagitis had esophageal walls that were twice as thick as those seen in healthy controls (mean thickness 4.2 mm versus 2.2 mm). After treatment, patients in the budesonide group showed decreases in the thickness of all wall layers, though only the decrease in the thickness of the mucosa was statistically significant. No adverse events were noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Topical versus systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data suggest that oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be slightly more effective than topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    for the treatment of eosinophilic esophagitis, but the degree of benefit probably does not justify routine use of prednisone considering the greater likelihood of side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/17\">",
"     17",
"    </a>",
"    ]. Furthermore, because of the high relapse rate, chronic or repeated therapy may be needed, which may also support the preferential use of swallowed fluticasone. If systemic steroids are used, the typical dose is 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    in divided doses (maximum 60 mg per day).",
"   </p>",
"   <p>",
"    A randomized trial compared topical with systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/45\">",
"     45",
"    </a>",
"    ]. The trial included 80 children with eosinophilic esophagitis who were randomly assigned to oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or swallowed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    . Almost all of the patients, regardless of treatment, were symptom free by four weeks. Histologic improvement was seen to a greater degree in the prednisone group. Relapse was observed in 45 percent of patients in both groups within 24 weeks of stopping therapy. Glucocorticoid side effects occurred in 40 percent of patients in the prednisone arm, whereas candidal esophagitis was seen in 15 percent in the fluticasone arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H209738\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL DILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilation of esophageal strictures is effective for relieving dysphagia, but has no effect on underlying inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. It is often reserved for patients who have failed more conservative therapy, but may be required as initial therapy in patients with high-grade strictures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/62\">",
"     62",
"    </a>",
"    ]. We generally reserve dilation for patients with strictures or rings who have not responded to medical therapy.",
"   </p>",
"   <p>",
"    Dilation should be performed carefully since it has been associated with deep mucosal tears and esophageal perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. It has been recommended that the progression of dilation per session be limited to 3 mm or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/64\">",
"     64",
"    </a>",
"    ]. Because of this, multiple dilations are often required to attain a goal esophageal diameter of 15 to 18 mm. Chest pain following the procedure is common and patients should be forewarned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether patients with eosinophilic esophagitis are at higher risk of perforation due to esophageal dilation than other patients undergoing dilation is not clear. Older studies suggested that patients with eosinophilic esophagitis are at increased risk for perforation, with perforation rates of 5 to 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/67\">",
"     67",
"    </a>",
"    ]. More recent studies suggest that the rate of perforation is considerably lower and is closer to that seen with esophageal dilation for strictures due to causes other than eosinophilic esophagitis (approximately 0.1 to 0.2 percent). A 2010 meta-analysis that included 468 patients who underwent 671 dilations found that while mucosal tears were described in a majority of cases, there was only one perforation (0.1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies subsequent to the meta-analysis have also shown lower perforation rates that originally reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 207 patients with eosinophilic esophagitis found no cases of perforation, though 74 percent of patients reported chest pain following the procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large series included 293 dilations in 167 patients performed between 1990 and 2009 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/64\">",
"       64",
"      </a>",
"      ]. Three of the procedures (1 percent) were complicated by a perforation. Risk factors included luminal narrowing in the upper or middle third of the esophagus, the presence of a stricture that could not be traversed with a standard upper endoscope, and the use of Savory dilators. Deep mucosal tears occurred in 9 percent of procedures and major bleeding occurred in 0.3 percent.",
"     </li>",
"     <li>",
"      A study of 70 dilations carried out in 36 patients had an overall complication rate of 7 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/69\">",
"       69",
"      </a>",
"      ]. There were two deep mucosal rents and three episodes of chest pain, but there were no perforations reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tearing and perforation can occur without perceived resistance when passing a dilator or the endoscope (",
"    <a class=\"graphic graphic_picture graphicRef50953 \" href=\"mobipreview.htm?33/59/34750\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/63\">",
"     63",
"    </a>",
"    ]. As a result, it may be reasonable to gently inspect the esophagus after passing each dilator. Rigid endoscopy has been associated with a high rate of perforation and should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/11\">",
"     11",
"    </a>",
"    ]. The use of glucocorticoids before dilation has not been extensively studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/70\">",
"     70",
"    </a>",
"    ]; it may offer a small benefit prior to dilation by diminishing inflammation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39305?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of benign esophageal strictures\", section on 'Complex strictures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H209105\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL AND INEFFECTIVE TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other treatments for eosinophilic esophagitis have been examined. Many have been ineffective, whereas others have shown efficacy in small series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antihistamines and cromolyn",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little benefit has been seen in patients treated with medications aimed at controlling allergies, including antihistamines and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    (a mast cell stabilizer) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Montelukast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial experience suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    (a leukotriene inhibitor that has been used in eosinophilic gastroenteritis) may be helpful for symptom reduction in patients with eosinophilic esophagitis but subsequent experience has been mixed. Thus, trials are required to clarify whether montelukast has a role in the management of eosinophilic esophagitis.",
"   </p>",
"   <p>",
"    The following are illustrative of the range of observations. Symptomatic improvement has been observed in small case series of both adult and pediatric patients with isolated eosinophilic esophagitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series examined eight adults who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/73\">",
"       73",
"      </a>",
"      ]. The dose used was much higher than the standard 10 mg dose used for the treatment of asthma in adults. While patients started at a dose of 10 mg per day, the patient increased the dose up to a suprapharmacologic dose totaling 100 mg daily based upon symptom relief. Once symptom relief had been achieved, the dose was reduced to maintenance levels where symptom control was maintained (20 to 40 mg daily). Six of eight patients had complete symptom relief. However, there was no effect on esophageal eosinophilia. Several side effects were observed, including nausea and myalgias. The safety of the high doses used in this study is unclear.",
"     </li>",
"     <li>",
"      In a retrospective series of eight pediatric patients who were maintained on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      (4 to 10 mg daily), three patients had a clinical response that was attributed to montelukast (one complete response and two partial responses) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/74\">",
"       74",
"      </a>",
"      ]. Four patients responded clinically but had also been started on other therapies in addition to the montelukast. The study was not able to confirm if montelukast had an effect on esophageal histology. No side effects were reported related to the montelukast.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By contrast,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    was not helpful in a patient with eosinophilic gastroenteritis with esophageal involvement in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/75\">",
"     75",
"    </a>",
"    ], while in another it was not effective in maintaining the histopathological or clinical response achieved by topical steroids in adults with eosinophilic esophagitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mepolizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mepolizumab is a humanized monoclonal antibody against interleukin (IL)-5, which has a central role in eosinophil recruitment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link&amp;anchor=H1536312#H1536312\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\", section on 'Environmental factors and T-cell immunity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of mepolizumab have had variable results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case series found clinical benefits in four patients with eosinophilic esophagitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A placebo-controlled trial in 11 adults found a reduction in esophageal eosinophilia in patients treated with mepolizumab compared with those who received placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/78\">",
"       78",
"      </a>",
"      ]. Clinically, there was a small improvement in dysphagia in the mepolizumab arm, but it did not differ significantly from improvement also seen the placebo arm.",
"     </li>",
"     <li>",
"      A third report included 57 children with eosinophilic esophagitis who were randomly assigned to three infusions of mepolizumab at different doses (0.55, 2.5, or 10",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/79\">",
"       79",
"      </a>",
"      ]. There was a significant decrease in the peak and mean eosinophil counts and improvement in endoscopic findings in all three groups. However, symptoms did not improve, possibly because most patients did not have severe symptoms at baseline. Whether the observed histologic end endoscopic benefits could be attributed to mepolizumab is uncertain since the study did not include a placebo arm and because dietary interventions were permitted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243557666\">",
"    <span class=\"h2\">",
"     Reslizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reslizumab is an IL-5 neutralizing antibody that is undergoing clinical trials in eosinophilic esophagitis.",
"    <strong>",
"    </strong>",
"    In a controlled trial involving 226 children and adolescents with eosinophilic esophagitis, there was a significant reduction in peak eosinophil counts compared with placebo (59, 67, and 64 percent for the three doses tested versus 24 percent for placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/80\">",
"     80",
"    </a>",
"    ]. However, all treatment groups had significant improvement in symptoms as assessed by a physician global assessment score and the differences were not significantly different than placebo. Thus, its role remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H439682448\">",
"    <span class=\"h2\">",
"     Anti-IgE monoclonal antibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a report of two patients with multiple food allergies and eosinophilic esophagitis, treatment with the anti-IgE monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    was associated with an improvement in allergic symptoms but not in endoscopic or histologic features of eosinophilic esophagitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Purine analogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case report described a clinical and histologic response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or 6-mercaptopurine in three adults with glucocorticoid-dependent eosinophilic esophagitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anti-TNF therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    was not effective at resolving symptoms or eosinophilia in a case series of three adults with glucocorticoid-dependent eosinophilic esophagitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term prognosis of eosinophilic esophagitis is unclear. Untreated, patients may remain symptomatic or have episodic symptoms. As noted above, symptoms frequently recur in patients treated with a short course of topical glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the disease persists into adulthood in affected children has not been extensively studied, although the available data suggest that it does. In a report of 620 children evaluated over a 14-year period, eosinophilic esophagitis persisted, with only 10 percent developing tolerance to their food allergies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/9\">",
"     9",
"    </a>",
"    ]. No children progressed to other gastrointestinal diseases.",
"   </p>",
"   <p>",
"    In adults, anecdotal observations suggest that the disease may progress to a fibrostenotic stage in which the predominant symptom is intermittent dysphagia, but the proportion of patients with progressive disease is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest study on the natural history in adults focused on 30 adults who were followed for an average of seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/16/44297/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients underwent a follow-up examination consisting of a structured interview, laboratory testing, and an upper endoscopy with biopsies. The majority of patients had persistent dysphagia. Attacks of dysphagia were more common in patients who had peripheral eosinophilia. Eosinophilic infiltration persisted in all symptomatic patients, but the degree of tissue eosinophilia appeared to decrease. The inflammatory process remained confined to the esophagus without gastric or duodenal involvement. No cases of dysplasia or esophageal malignancy were observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7984095\">",
"    <span class=\"h1\">",
"     PATIENT ADVOCACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Partnership for Eosinophilic Disorders (",
"    <a class=\"external\" href=\"file://apfed.org/drupal/drupal/index.php\">",
"     apfed.org/drupal/drupal/index.php",
"    </a>",
"    ) is an advocacy group for patients with eosinophilic gastrointestinal diseases.",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/54/39778?source=see_link\">",
"       \"Patient information: Eosinophilic esophagitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of eosinophilic esophagitis includes pharmacologic, endoscopic, and dietary interventions. Our recommendations below are consistent with consensus guidelines (",
"    <a class=\"graphic graphic_table graphicRef58642 \" href=\"mobipreview.htm?28/13/28895\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We refer both adults and children to an allergist with expertise in the evaluation of food allergies. We suggest avoidance of known allergens (both food and environmental) for patients in whom specific allergies can be identified after discussion of the pros and cons of the dietary approach as described above&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2895691\">",
"       'Dietary therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dietary approaches have been best studied in children, in whom they are used routinely as an option for primary therapy. Emerging data in adults suggest a six-food elimination diet can improve symptoms and esophageal eosinophilia and help identify causative foods. As a result, some authorities have begun recommending this approach as a primary option for their adult patients. If a dietary approach is taken, it is important to coordinate it with a nutritionist since elimination and elemental diets can result in important restrictions of calories and nutrients.",
"     </li>",
"     <li>",
"      In patients who opt for a pharmacologic approach, we suggest treatment with swallowed",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Fluticasone propionate'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Fluticasone is administered using a metered dose inhaler without a spacer. The medication is sprayed into the patient&rsquo;s mouth and then swallowed. Patients should not use a spacer or inhale while the medication is being delivered, and they should not eat or drink for 30 minutes following administration. The dose used varies with the age of the patient.",
"      <br/>",
"      <br/>",
"      We suggest initial treatment for six to eight weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Optimal strategies after initial treatment are unsettled. Thus, the decision to continue treatment should be individualized. Because symptoms and esophageal eosinophilia almost universally return when treatment is discontinued, we suggest ongoing treatment, whether medical or nutritional (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Some authorities treat on an as-needed basis. Such an approach is particularly useful in patients who have identifiable, seasonal triggers. Others use the lowest dose possible of topical glucocorticoids that allow patients to remain asymptomatic. Our approach is to continue nutritional therapy, using topical glucocorticoids as needed in doses and intervals that keep patients asymptomatic.",
"      <br/>",
"      <br/>",
"      Treatment is generally well-tolerated. However, worsening of dysphagia during treatment should alert to the possibility of candidal esophagitis.",
"     </li>",
"     <li>",
"      In patients who do not respond to topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      , we suggest either an elimination diet (if not already tried) or a trial of topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2895768\">",
"       'Elimination diets'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Budesonide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adult patients with esophageal rings or strictures may require dilation. Dilation is associated with mucosal tears and esophageal perforation and thus should be performed extremely cautiously. We suggest that, if possible, dilation be avoided until patients have been given a course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      , which may relieve dysphagia and thus avoid the need for dilation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Dilation has generally not been needed in children in most reports. (See",
"      <a class=\"local\" href=\"#H209738\">",
"       'Esophageal dilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of acid suppression is unclear. Acid suppression is reasonable in patients in whom reflux is suspected to be contributing to symptoms and there are occasional patients who have a good clinical response to proton pump inhibitors. Thus, we suggest a trial of a proton pump inhibitor except in patients who have already tried one and did not respond (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acid suppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whether patients should undergo surveillance endoscopy is unclear. Although a malignant potential has not been reported, follow-up has generally been short. We generally repeat upper endoscopy for patients in whom symptoms have changed or who require esophageal dilation.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/1\">",
"      MacCarty RL, Talley NJ. Barium studies in diffuse eosinophilic gastroenteritis. Gastrointest Radiol 1990; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/2\">",
"      Dobbins JW, Sheahan DG, Behar J. Eosinophilic gastroenteritis with esophageal involvement. Gastroenterology 1977; 72:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/3\">",
"      Kukuruzovic RH, Elliott EE, O'Loughlin EV, Markowitz JE. Non-surgical interventions for eosinophilic oesophagitis. Cochrane Database Syst Rev 2004; :CD004065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/4\">",
"      Rothenberg ME. Biology and treatment of eosinophilic esophagitis. Gastroenterology 2009; 137:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/5\">",
"      Dellon ES. Diagnosis and management of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012; 10:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/6\">",
"      Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/7\">",
"      Straumann A, Spichtin HP, Grize L, et al. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003; 125:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/8\">",
"      Lieberman JA, Morotti RA, Konstantinou GN, et al. Dietary therapy can reverse esophageal subepithelial fibrosis in patients with eosinophilic esophagitis: a historical cohort. Allergy 2012; 67:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/9\">",
"      Spergel JM, Brown-Whitehorn TF, Beausoleil JL, et al. 14 years of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr 2009; 48:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/10\">",
"      Spergel JM. Eosinophilic esophagitis in adults and children: evidence for a food allergy component in many patients. Curr Opin Allergy Clin Immunol 2007; 7:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/11\">",
"      Straumann A, Bussmann C, Zuber M, et al. Eosinophilic esophagitis: analysis of food impaction and perforation in 251 adolescent and adult patients. Clin Gastroenterol Hepatol 2008; 6:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/12\">",
"      Klinnert MD. Psychological impact of eosinophilic esophagitis on children and families. Immunol Allergy Clin North Am 2009; 29:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/13\">",
"      Santangelo CM, McCloud E. Nutritional management of children who have food allergies and eosinophilic esophagitis. Immunol Allergy Clin North Am 2009; 29:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/14\">",
"      Spergel JM, Beausoleil JL, Mascarenhas M, Liacouras CA. The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J Allergy Clin Immunol 2002; 109:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/15\">",
"      Spergel JM, Andrews T, Brown-Whitehorn TF, et al. Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Ann Allergy Asthma Immunol 2005; 95:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/16\">",
"      Penfield JD, Lang DM, Goldblum JR, et al. The role of allergy evaluation in adults with eosinophilic esophagitis. J Clin Gastroenterol 2010; 44:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/17\">",
"      Liacouras CA, Spergel JM, Ruchelli E, et al. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 2005; 3:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/18\">",
"      Assa'ad A. Detection of causative foods by skin prick and atopy patch tests in patients with eosinophilic esophagitis: things are not what they seem. Ann Allergy Asthma Immunol 2005; 95:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/19\">",
"      Henderson CJ, Abonia JP, King EC, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2012; 129:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/20\">",
"      Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006; 4:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/21\">",
"      Gonsalves N, Yang GY, Doerfler B, et al. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 2012; 142:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/22\">",
"      Lucendo AJ, Arias A, Gonz&aacute;lez-Cervera J, et al. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: A&nbsp;prospective study on the food cause of the disease. J Allergy Clin Immunol 2013; 131:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/23\">",
"      Kelly KJ, Lazenby AJ, Rowe PC, et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology 1995; 109:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/24\">",
"      Markowitz JE, Spergel JM, Ruchelli E, Liacouras CA. Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol 2003; 98:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/25\">",
"      Peterson KA, Byrne KR, Vinson LA, et al. Elemental Diet Induces Histologic Response in Adult Eosinophilic Esophagitis. Am J Gastroenterol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/26\">",
"      Remedios M, Campbell C, Jones DM, Kerlin P. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc 2006; 63:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/27\">",
"      Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol 2007; 102:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/28\">",
"      Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/29\">",
"      Orenstein SR, Shalaby TM, Di Lorenzo C, et al. The spectrum of pediatric eosinophilic esophagitis beyond infancy: a clinical series of 30 children. Am J Gastroenterol 2000; 95:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/30\">",
"      Krarup AL, Villadsen GE, Mejlgaard E, et al. Acid hypersensitivity in patients with eosinophilic oesophagitis. Scand J Gastroenterol 2010; 45:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/31\">",
"      Peterson KA, Thomas KL, Hilden K, et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci 2010; 55:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/32\">",
"      Moawad FJ, Veerappan GR, Dias JA, et al. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol 2013; 108:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/33\">",
"      Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006; 131:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/34\">",
"      Alexander JA, Jung KW, Arora AS, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012; 10:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/35\">",
"      Aceves SS, Furuta GT, Spechler SJ. Integrated approach to treatment of children and adults with eosinophilic esophagitis. Gastrointest Endosc Clin N Am 2008; 18:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/36\">",
"      Noel RJ, Putnam PE, Collins MH, et al. Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. Clin Gastroenterol Hepatol 2004; 2:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/37\">",
"      Faubion WA Jr, Perrault J, Burgart LJ, et al. Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr 1998; 27:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/38\">",
"      Langdon DE. Fluticasone in eosinophilic corrugated ringed esophagus. Am J Gastroenterol 2001; 96:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/39\">",
"      Perrault J, Smyrk T, Burgart L, Arora A. The varied presentations of eosinophilic esophagitis in adults: GERD it is not! (abstract). Gastroenterology 2001; 120:A250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/40\">",
"      Teitelbaum JE, Fox VL, Twarog FJ, et al. Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. Gastroenterology 2002; 122:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/41\">",
"      Dohil R, Newbury R, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010; 139:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/42\">",
"      Hirano I. Therapeutic end points in eosinophilic esophagitis: is elimination of esophageal eosinophils enough? Clin Gastroenterol Hepatol 2012; 10:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/43\">",
"      Helou EF, Simonson J, Arora AS. 3-yr-follow-up of topical corticosteroid treatment for eosinophilic esophagitis in adults. Am J Gastroenterol 2008; 103:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/44\">",
"      Arora AS, Perrault J, Smyrk TC. Topical corticosteroid treatment of dysphagia due to eosinophilic esophagitis in adults. Mayo Clin Proc 2003; 78:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/45\">",
"      Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008; 6:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/46\">",
"      Lindberg GM, Van Eldik R, Saboorian MH. A case of herpes esophagitis after fluticasone propionate for eosinophilic esophagitis. Nat Clin Pract Gastroenterol Hepatol 2008; 5:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/47\">",
"      Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/48\">",
"      Wagener JS, Wojtczak HA. Inhaled steroids in children: risks versus rewards. J Pediatr 1998; 132:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/49\">",
"      Aceves SS, Dohil R, Newbury RO, Bastian JF. Topical viscous budesonide suspension for treatment of eosinophilic esophagitis. J Allergy Clin Immunol 2005; 116:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/50\">",
"      Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am J Gastroenterol 2007; 102:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/51\">",
"      Karnam U, Hirano I. Effectiveness of oral budesonide suspension in adult patients with eosinophilic esophagitis (abstract). Gastroenterology 2008; 134 (Suppl):A289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/52\">",
"      Netzer P, Gschossmann JM, Straumann A, et al. Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J Gastroenterol Hepatol 2007; 19:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/53\">",
"      Straumann A, Degen L, Felder S. Budesonide as induction treatment for active eosinophilic esophagitis in adolescents and adults: a randomized, double-blind, placebo-controlled study (Bee-I trial) (abstract). Gastroenterology 2008; 134 (Suppl):A104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/54\">",
"      Straumann A, Conus S, Degen L, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011; 9:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/55\">",
"      Straumann A, Conus S, Degen L, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010; 139:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/56\">",
"      Dellon ES, Sheikh A, Speck O, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology 2012; 143:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/57\">",
"      Stoeck M, Riedel R, Hochhaus G, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther 2004; 309:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/58\">",
"      Schroeder S, Fleischer DM, Masterson JC, et al. Successful treatment of eosinophilic esophagitis with ciclesonide. J Allergy Clin Immunol 2012; 129:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/59\">",
"      Lee JJ, Fried AJ, Hait E, et al. Topical inhaled ciclesonide for treatment of eosinophilic esophagitis. J Allergy Clin Immunol 2012; 130:1011; author reply 1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/60\">",
"      Schoepfer AM, Gonsalves N, Bussmann C, et al. Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol 2010; 105:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/61\">",
"      Robles-Medranda C, Villard F, le Gall C, et al. Severe dysphagia in children with eosinophilic esophagitis and esophageal stricture: an indication for balloon dilation? J Pediatr Gastroenterol Nutr 2010; 50:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/62\">",
"      Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007; 133:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/63\">",
"      Kaplan M, Mutlu EA, Jakate S, et al. Endoscopy in eosinophilic esophagitis: \"feline\" esophagus and perforation risk. Clin Gastroenterol Hepatol 2003; 1:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/64\">",
"      Jung KW, Gundersen N, Kopacova J, et al. Occurrence of and risk factors for complications after endoscopic dilation in eosinophilic esophagitis. Gastrointest Endosc 2011; 73:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/65\">",
"      Cohen MS, Kaufman AB, Palazzo JP, et al. An audit of endoscopic complications in adult eosinophilic esophagitis. Clin Gastroenterol Hepatol 2007; 5:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/66\">",
"      Eisenbach C, Merle U, Schirmacher P, et al. Perforation of the esophagus after dilation treatment for dysphagia in a patient with eosinophilic esophagitis. Endoscopy 2006; 38 Suppl 2:E43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/67\">",
"      Hirano I. Dilation in eosinophilic esophagitis: to do or not to do? Gastrointest Endosc 2010; 71:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/68\">",
"      Jacobs JW Jr, Spechler SJ. A systematic review of the risk of perforation during esophageal dilation for patients with eosinophilic esophagitis. Dig Dis Sci 2010; 55:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/69\">",
"      Dellon ES, Gibbs WB, Rubinas TC, et al. Esophageal dilation in eosinophilic esophagitis: safety and predictors of clinical response and complications. Gastrointest Endosc 2010; 71:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/70\">",
"      Schoepfer AM, Gschossmann J, Scheurer U, et al. Esophageal strictures in adult eosinophilic esophagitis: dilation is an effective and safe alternative after failure of topical corticosteroids. Endoscopy 2008; 40:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/71\">",
"      Losurdo J, Bruninga K, Dobozi B. Idiopathic eosinophilic esophagitis: A new cause of \"feline\" esophagus (abstract). Gastroenterology 1999; 116:A239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/72\">",
"      Walsh SV, Antonioli DA, Goldman H, et al. Allergic esophagitis in children: a clinicopathological entity. Am J Surg Pathol 1999; 23:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/73\">",
"      Attwood SE, Lewis CJ, Bronder CS, et al. Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut 2003; 52:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/74\">",
"      Stumphy J, Al-Zubeidi D, Guerin L, et al. Observations on use of montelukast in pediatric eosinophilic esophagitis: insights for the future. Dis Esophagus 2011; 24:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/75\">",
"      Daikh BE, Ryan CK, Schwartz RH. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture. Ann Allergy Asthma Immunol 2003; 90:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/76\">",
"      Lucendo AJ, De Rezende LC, Jim&eacute;nez-Contreras S, et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig Dis Sci 2011; 56:3551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/77\">",
"      Stein ML, Collins MH, Villanueva JM, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006; 118:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/78\">",
"      Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010; 59:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/79\">",
"      Assa'ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011; 141:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/80\">",
"      Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012; 129:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/81\">",
"      Rocha R, Vitor AB, Trindade E, et al. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr 2011; 170:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/82\">",
"      Straumann A, Bussmann C, Conus S, et al. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol 2008; 122:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/16/44297/abstract/83\">",
"      Attwood SE, Smyrk TC, Demeester TR, Jones JB. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci 1993; 38:109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2247 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44297=[""].join("\n");
var outline_f43_16_44297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60192545\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2895691\">",
"      DIETARY THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2895768\">",
"      Elimination diets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83815940\">",
"      - Elimination diets in children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83815947\">",
"      - Elimination diets in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2895775\">",
"      Elemental diets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H209980\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acid suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Topical glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fluticasone propionate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Budesonide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H450744934\">",
"      - Ciclesonide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H210774\">",
"      - Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Topical versus systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H209738\">",
"      ESOPHAGEAL DILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H209105\">",
"      EXPERIMENTAL AND INEFFECTIVE TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antihistamines and cromolyn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Montelukast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mepolizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H243557666\">",
"      Reslizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H439682448\">",
"      Anti-IgE monoclonal antibody",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Purine analogues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anti-TNF therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7984095\">",
"      PATIENT ADVOCACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2247\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2247|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/59/34750\" title=\"picture 1\">",
"      Eosinophilic esophagitis mucosal tear post-dilation Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2247|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/13/28895\" title=\"table 1\">",
"      Eosinophilic esophagitis recommendations summary TIGERS 2011",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/54/39778?source=related_link\">",
"      Patient information: Eosinophilic esophagitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_16_44298="Right bundle branch block 1";
var content_f43_16_44298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65619%7ECARD%2F64393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65619%7ECARD%2F64393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Complete right bundle branch block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 142px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The initial myocardial activation is normal; thus, there is a normal septal q wave in leads 1 and V6, followed by a tall R wave. Similarly, there is a normal initial septal R wave followed by a deep S wave in leads aVR and V1. However, the subsequent abnormal right ventricular activation occurs from left to right and goes through the ventricular myocardium instead of the His-Purkinje system; thus, there will be a tall and broad secondary R wave (R') in leads aVR and V1 (a RSR' complex), and a deep and broad S wave in leads I and V6. The width of the QRS complex is &gt;0.12 sec.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1212px;\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Common RBBB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram showing characteristic changes in the precordial leads in common RBBB. The asynchronous activation of the two ventricles increases the QRS duration (0.13 sec). The terminal forces are rightward and anterior due the delayed activation of the right ventricle, resulting in an rsR' pattern in the anterior-posterior lead V1 and a wide negative S wave in the left-right lead V6 (and, not shown, in lead I).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44298=[""].join("\n");
var outline_f43_16_44298=null;
var title_f43_16_44299="HCV lookback at blood centers";
var content_f43_16_44299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    HCV lookback experiences of Canadian and European blood centers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number recipients target",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent deceased",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent HCV+ pre-lookback",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number tested",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent HCV positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wall, 1997, Toronto",
"       </td>",
"       <td>",
"        1990-5",
"       </td>",
"       <td>",
"        2418",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        68*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Christensen, 1977, Denmark",
"       </td>",
"       <td>",
"        1991-6",
"       </td>",
"       <td>",
"        1006",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vrielink, 1995, Netherlands",
"       </td>",
"       <td>",
"        1990-2",
"       </td>",
"       <td>",
"        270",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        32*",
"       </td>",
"       <td>",
"        81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lau, 1997, Toronto",
"       </td>",
"       <td>",
"        1990-5",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goldman, 1998, Canada",
"       </td>",
"       <td>",
"        1995-97",
"       </td>",
"       <td>",
"        1779",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        NK",
"       </td>",
"       <td>",
"        580",
"       </td>",
"       <td>",
"        58",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not available NK: not known.",
"     <br>",
"      * Without other risk factors.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44299=[""].join("\n");
var outline_f43_16_44299=null;
var title_f43_16_44300="Karnofsky performance status scale";
var content_f43_16_44300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58785%7EHEME%2F72901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58785%7EHEME%2F72901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Karnofsky performance status scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Value",
"       </td>",
"       <td class=\"subtitle1\">",
"        Level of functional capacity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        Normal, no complaints, no evidence of disease",
"       </td>",
"       <td rowspan=\"3\">",
"        Able to carry on normal activity and to work; no special care needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        Able to carry on normal activity, minor signs or symptoms of disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        Normal activity with effort, some signs or symptoms of disease",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        Cares for self, unable to carry on normal activity or to do active work",
"       </td>",
"       <td rowspan=\"3\">",
"        Unable to work; able to live at home and care for most personal needs; various degrees of assistance needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        Requires occasional assistance, but is able to care for most needs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        Requires considerable assistance and frequent medical care",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        Disabled, requires special care and assistance",
"       </td>",
"       <td rowspan=\"5\">",
"        Unable to care for self; requires equivalent of institutional or hospital care; disease may be progressing rapidly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Severely disabled, hospitalization is indicated although death is not imminent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        Hospitalization is necessary, very sick, active supportive treatment necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        Moribund, fatal processes progressing rapidly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Dead",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Eastern Cooperative Oncology Group (ECOG, Zubrod, WHO) performance scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Performance status",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        Fully active; no performance restrictions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Strenuous physical activity restricted; fully ambulatory and able to carry out light work",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Capable of all selfcare but unable to carry out any work activities. Up and about &gt;50 percent of waking hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Capable of only limited selfcare; confined to bed or chair &gt;50 percent of waking hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        Completely disabled; cannot carry out any selfcare; totally confined to bed or chair",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Excerpted from: Oken MM, et al. Am J Clin Oncol 1982; 5:649.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44300=[""].join("\n");
var outline_f43_16_44300=null;
var title_f43_16_44301="Galactose metabolism";
var content_f43_16_44301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metabolic pathway of galactose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 444px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Deficiency of any of the enzymes (in blue) may result in galactosemia. Galactose-1-phosphate is elevated if GALT or epimerase activity is absent or impaired.",
"    <div class=\"footnotes\">",
"     GALT: galactose-1-phosphate uridyl transferase; UDP: uridine diphosphate.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44301=[""].join("\n");
var outline_f43_16_44301=null;
var title_f43_16_44302="Combined exophytic-endophytic retinoblastoma";
var content_f43_16_44302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Combined exophytic-endophytic retinoblastoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Exophytic retinoblastoma that has eroded through the overlying retina and into the vitreous cavity, giving the clinical appearance of a combined exophytic-endophytic lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ronald GW Teed, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44302=[""].join("\n");
var outline_f43_16_44302=null;
var title_f43_16_44303="Intraarticular metatarsal head fracture";
var content_f43_16_44303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraarticular metatarsal head fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A fracture into the joint space of the fourth metatarsal is indicated by the arrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH and James R Clugston, MD, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_16_44303=[""].join("\n");
var outline_f43_16_44303=null;
